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Abstract: The clinical significance of copy number variants (CNVs) in 
congenital heart disease (CHD) continues to be a challenge. Although CNVs 
including genes can confer disease risk, relationships between gene dosage 
and phenotype are still being defined. Our goal was to perform a quantitative 
analysis of CNVs involving 100 well-defined CHD risk genes identified through 
previously published human association studies in subjects with anatomically 
defined cardiac malformations. A novel analytical approach permitting CNV 
gene frequency “spectra” to be computed over prespecified regions to 
determine phenotype-gene dosage relationships was employed. CNVs in 
subjects with CHD (n = 945), subphenotyped into 40 groups and verified in 
accordance with the European Paediatric Cardiac Code, were compared with 
two control groups, a disease-free cohort (n = 2,026) and a population with 
coronary artery disease (n = 880). Gains (≥200 kb) and losses (≥100 kb) 
were determined over 100 CHD risk genes and compared using a Barnard 
exact test. Six subphenotypes showed significant enrichment (P ≤ 0.05), 
including aortic stenosis (valvar), atrioventricular canal (partial), 
atrioventricular septal defect with tetralogy of Fallot, subaortic stenosis, 
tetralogy of Fallot, and truncus arteriosus. Furthermore, CNV gene frequency 
spectra were enriched (P ≤ 0.05) for losses at: FKBP6, ELN, GTF2IRD1, 
GATA4, CRKL, TBX1, ATRX, GPC3, BCOR, ZIC3, FLNA and MID1; and gains 
at: PRKAB2, FMO5, CHD1L, BCL9, ACP6, GJA5, HRAS, GATA6 and RUNX1. Of 
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CHD subjects, 14% had causal chromosomal abnormalities, and 4.3% had 
likely causal (significantly enriched), large, rare CNVs. CNV frequency spectra 
combined with precision phenotyping may lead to increased molecular 
understanding of etiologic pathways. 
Keywords: congenital heart disease, copy number variation, genetics 
Structural congenital heart disease (CHD) is the most common 
form of congenital malformations, affecting 0.8% of live births.21 Other 
than infection, more children die from CHD in infancy than from all 
other forms of disease.25 In addition, it is estimated that at least 10% 
of early miscarriages are a consequence of severe cardiac 
malformations.10 The causes of congenital cardiac malformations are 
largely unknown. It is estimated that 18% are due to chromosomal 
causes or genetic structural abnormalities including trisomies (Trisomy 
21, 13, and 18) as well as deletion syndromes; all of these are 
associated with significant disease risk for CHD.36 A small percentage 
of congenital cardiac malformations are disorders in which underlying 
single genes have been discovered such as TBX5 in Holt-Oram 
syndrome; JAG1 in Alagille syndrome; and PTPN11, SOS1, and KRAS 
in Noonan syndrome.36 Known environmental risk factors during 
pregnancy, such as maternal diabetes or prenatal exposure to drugs, 
viruses, and reduced folate intake account for a small percentage of 
CHD cases.16,24 Although our understanding of molecular pathways in 
cardiac development has grown tremendously in the past few years, 
the etiology of human and clinically relevant CHD in the majority 
(∼75%) of cases cannot yet be identified or explained.14,16 
The widespread use of microarray-based genomic technologies 
over the past 5–6 yr have implicated copy number variants (CNVs) in 
numerous disorders such as neuropsychiatric diseases,49 craniofacial 
phenotypes, cancer, and congenital anomalies including CHD.7,18,35,36 
Relative to sequence variations such as single base-pair mutations or 
single nucleotide polymorphisms (SNPs), rare and large CNVs are 
hypothesized to confer higher disease risk as entire genes are deleted 
or duplicated.12,31 However, poor reproducibility between microarray 
platforms and the lack of standardized analytical tools highlight the 
importance of careful filtering in CNV detection studies.37 Nondisease-
related copy number polymorphisms (CNPs and/or common CNVs 
≥1%) are abundant, as evidenced by the growing Database of 
Genomic Variants (DGV).22,57 Similar to the challenges in the sequence 
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analysis of unique genetic variants, the discovery of rare etiologic 
CNVs remains a challenge, both because it is more difficult to detect a 
rare event over another event seen many times and because of the 
intrinsic low prior probability of there being such a variant at any 
particular location in the genome in any individual.28 
Recently, an algorithm to clinically interpret CNVs in patients 
with CHD was described.6 This approach is primarily based on gene 
content and overlap with known causal CHD syndromes, rather than 
on CNV inheritance and size.6 We employed a parallel approach in this 
study and utilized a strict criteria to define “likely causal” duplications 
or deletions, in well-established human CHD risk genes. We chose 100 
CHD risk genes or regions that were supported by published 
observations in human studies as a means to identify potentially 
disease-relevant CNVs. A majority of these known CHD risk genes 
were previously described or could be identified through the CHD WIKI 
portal.1,36 In addition, genes associated with recognized causal 
chromosomal abnormalities in CHD were included, as well as recently 
identified candidate genes from association studies (see Table 1).1,42 
Table 1. Known CHD risk genes 
Gene Gene Name Cytoban
d 
Gene 
Start 
Gene 
Size 
ABI CN Assay 
# 
CHD 
WIK
I 
OMIM 
ID 
PubMed 
ID 
ACP6 ACID PHOSPHATASE 6, 
LYSOPHOSPHATIDE 
1q21.1 14558579
1 
23467 Hs00320736_c
n 
 
61147
1 
15117819, 
19597493 
ACTC1 ACTIN, ALPHA, CARDIAC 
MUSCLE 
15q14 32867588 7631 
 
NS 10254
0 
17611253, 
17947298 
ACVR2B ACTIVIN A RECEPTOR, 
TYPE IIB 
3p22.2 38470793 38844 
 
NS 60273
0 
20193066 
ALDH1A2 ALDEHYDE 
DEHYDROGENASE 1 
FAMILY, MEMBER A2 
15q22.1 56032918 11228
0 
 
NS 60368
7 
19886994 
ANKRD1 ANKYRIN REPEAT 
DOMAIN-CONTAINING 
PROTEIN 1 
10q23.31 92661836 9176 
 
NS 60959
9 
18273862, 
20193066 
ASXL2 ADDITIONAL SEX COMBS-
LIKE 2 
2p23.3 25815756 13906
0 
  
61299
1 
19597493 
ATRX ATR-X GENE Xq21.1 76647011 28136
4 
 
S 30003
2 
20193066 
BCL9 B-CELL CLL/LYMPHOMA 9 1q21.1 14547980
5 
84834 Hs01608359_c
n 
 
60259
7 
15117819, 
19597493 
BCOR BCL6 COREPRESSOR Xp11.4 39795442 46221 Hs02764783_c
n 
S 30048
5 
15770227 
BRAF V-RAF MURINE SARCOMA 
VIRAL ONCOGENE 
HOMOLOG B1 
7q34 14008028
1 
19075
2 
 
S 16475
7 
16474404, 
19206169 
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Gene Gene Name Cytoban
d 
Gene 
Start 
Gene 
Size 
ABI CN Assay 
# 
CHD 
WIK
I 
OMIM 
ID 
PubMed 
ID 
CBL CAS-BR-M MURINE 
ECOTROPIC RETROVIRAL 
TRANSFORMING 
SEQUENCE HOMOLOG 
11q23.3 11858219
9 
10187
0 
  
16536
0 
15266616 
CFC1 CRYPTIC PROTEIN 2q21.1 13106680
4 
6748 
 
NS, 
S 
60519
4 
11062482 
CHD1L CHROMODOMAIN 
HELICASE DNA-BINDING 
PROTEIN 1-LIKE 
1q21.1 14518091
4 
53153 Hs00327255_c
n 
 
61303
9 
15117819, 
19597493 
CHD7 CHROMODOMAIN 
HELICASE DNA-BINDING 
PROTEIN 7 
8q12.2 61753892 18812
9 
Hs01604098_c
n 
S 60889
2 
15300250 
     
Hs01362863_c
n 
   
CITED2 CBP/p300-INTERACTING 
TRANSACTIVATOR, WITH 
GLU/ASP-RICH C-
TERMINAL DOMAIN 
6q24.1 13973509
1 
2387 
 
NS 60293
7 
16287139 
COL2A1 COLLAGEN, TYPE II, 
ALPHA-1 
12q13.11 46653014 31538 Hs00560273_c
n 
S 12014
0 
20193066 
CRELD1 CYSTEINE-RICH PROTEIN 
WITH EGF-LIKE DOMAINS 
1 
3p25.3 9950505 11585 
 
NS 60717
0 
12632326 
CRKL V-CRK AVIAN SARCOMA 
VIRUS CT10 ONCOGENE 
HOMOLOG-LIKE 
22q11.21 19601713 36177 Hs01301005_c
n 
 
60200
7 
20494672*
* 
CSDE1 COLD-SHOCK DOMAIN-
CONTAINING E1, RNA-
BINDING 
1p13.2 11506105
9 
41135 
 
S 19151
0 
20193066 
EHMT1 EUCHROMATIC HISTONE 
METHYLTRANSFERASE 1 
9q34.3 13972523
7 
12516
2 
Hs00150023_c
n 
S 60700
1 
16826528, 
20193066 
ELN ELASTIN 7q11.23 73080362 41810 Hs03073113_c
n 
NS, 
S 
13016
0 
12952863 
EVC ELLIS-VAN CREVELD 
SYNDROME 
4p16.1 5763824 10310
8 
 
S 22550
0 
12571802 
EVC2 EVC2 GENE 4p16.1 5615052 14614
3 
 
S 60726
1 
12571802 
FBN1 FIBRILLIN 1 15q21.1 46487796 23741
4 
 
S 13479
7 
10441597, 
18412115 
FKBP6 FK506-BINDING PROTEIN 
6 
7q11.23 72380235 30342 Hs03635913_c
n 
 
60483
9 
12952863 
     
Hs03630484_c
n 
   
FLNA FILAMIN A Xq28 15323009
3 
26107 
 
S 30001
7 
17190868 
FMO5 FLAVIN-CONTAINING 
MONOOXYGENASE 5 
1q21.1 14512446
1 
39085 Hs02744463_c
n 
 
60395
7 
15117819, 
19597493 
FOXC1 FORKHEAD BOX C1 6p25.3 1555679 3449 Hs02241194_c
n 
S 60109
0 
15654696 
FOXH1 FORKHEAD BOX H1 8q24.3 14567031
6 
2210 
 
NS 60362
1 
18538293 
FOXL2 FORKHEAD 
TRANSCRIPTION FACTOR 
FOXL2 
3q22.3 14014575
5 
2736 Hs01045878_c
n 
S 60559
7 
18642388, 
20193066 
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Gene Gene Name Cytoban
d 
Gene 
Start 
Gene 
Size 
ABI CN Assay 
# 
CHD 
WIK
I 
OMIM 
ID 
PubMed 
ID 
FOXL2 FORKHEAD 
TRANSCRIPTION FACTOR 
FOXL2 
3q22.3 14014575
5 
2736 Hs01045878_c
n 
S 60559
7 
18642388, 
20193066 
GATA4 GATA-BINDING PROTEIN 
4 
8p23.1 11599125 55793 Hs01321405_c
n 
NS 60057
6 
16025100 
GATA6 GATA-BINDING PROTEIN 
6 
18q11.2 18003413 32812 Hs02615249_c
n 
NS 60165
6 
19666519 
GDF1 GROWTH/DIFFERENTIATI
ON FACTOR 1 
19p13.11 18840360 27593 Hs07489748_c
n 
NS 60288
0 
17924340 
GJA1 GAP JUNCTION PROTEIN, 
ALPHA-1 
6q22.31 12179844
3 
14129 
 
S 12101
4 
11470490 
GJA5 GAP JUNCTION PROTEIN, 
ALPHA-5 
1q21.1 14569495
5 
17153 Hs00597111_c
n 
NS 12101
3 
15117819 
GPC3 GLYPICAN 3 Xq26.2 13249744
1 
44989
1 
Hs00702786_c
n 
S 30003
7 
10232747, 
20193066 
GTF2IRD1 GTF2I REPEAT DOMAIN-
CONTAINING PROTEIN 1 
7q11.23 73506055 14879
3 
  
60431
8 
12952863 
HAND1 HEART- AND NEURAL 
CREST DERIVATIVES-
EXPRESSED 1 
5q33.2 15383472
4 
3293 
  
60240
6 
10189962 
HEY2 HAIRY/ENHANCER OF 
SPLIT-RELATED WITH 
YRPW MOTIF 2 
6q22.31 12611242
4 
11684 
 
NS 60467
4 
20193066 
HOXA1 HOMEOBOX A1 7p15.2 27099138 3012 Hs00428080_c
n 
S 14295
5 
16155570 
HRAS V-HA-RAS HARVEY RAT 
SARCOMA VIRAL 
ONCOGENE HOMOLOG 
11p15.5 522241 3309 Hs00137975_c
n 
S 19002
0 
17054105 
ISL1 ISL LIM HOMEOBOX 1 5q11.2 50714714 11606 
  
60036
6 
20520780 
JAG1 JAGGED 1 20p12.2 10566331 36363 
 
NS, 
S 
60192
0 
11152664 
KIF3C KINESIN FAMILY MEMBER 
3C 
2p23.3 26002958 55989 
  
60284
5 
19597493 
KRAS V-KI-RAS2 KIRSTEN RAT 
SARCOMA VIRAL 
ONCOGENE HOMOLOG 
12p12.1 25249446 45675 
 
S 19007
0 
16474405, 
16474404 
LBR LAMIN B RECEPTOR 1q42.12 22365582
6 
27316 
 
S 60002
4 
20193066 
LEFTY1 LEFT-RIGHT 
DETERMINATION FACTOR 
1 
1q42.12 22414060
4 
2855 
  
60303
7 
10053005 
LEFTY2 LEFT-RIGHT 
DETERMINATION FACTOR 
2 
1q42.12 22419092
5 
4618 
 
NS 60187
7 
10053005 
MAP2K1 MITOGEN-ACTIVATED 
PROTEIN KINASE KINASE 
1 
15q22.31 64466264 10467
2 
 
S 17687
2 
18042262 
MAP2K2 MITOGEN-ACTIVATED 
PROTEIN KINASE KINASE 
2 
19p13.3 4041319 33807 
 
S 60126
3 
18042262 
MAP3K7IP
2 
MITOGEN-ACTIVATED 
PROTEIN KINASE KINASE 
KINASE 7 
6q25.1 14968075
5 
93687 
 
NS 60261
4 
20493459 
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Gene Gene Name Cytoban
d 
Gene 
Start 
Gene 
Size 
ABI CN Assay 
# 
CHD 
WIK
I 
OMIM 
ID 
PubMed 
ID 
MAPK1 MITOGEN-ACTIVATED 
PROTEIN KINASE 1 
q11.21–
22q11. 
20443946 10802
4 
Hs02937892_c
n 
 
17694
8 
21127295*
* 
MED13L MEDIATOR COMPLEX 
SUBUNIT 13-LIKE 
12q24.21 11488076
3 
31876
3 
 
NS 60877
1 
14638541 
MGP MATRIX GAMMA-
CARBOXYGLUTAMIC ACID 
12p12.3 14926093 4002 
 
S 15487
0 
9916809, 
20193066 
MID1 MIDLINE 1 Xp22.2 10373595 38813
5 
Hs02158662_c
n 
S 30055
2 
12833403, 
20193066 
     
Hs02784563_c
n 
   
MLL2 MYELOID/LYMPHOID OR 
MIXED LINEAGE 
LEUKEMIA 2 
12q13.12 47699024 36350 
 
S 60211
3 
20711175 
MYH11 MYOSIN, HEAVY CHAIN 
11, SMOOTH MUSCLE 
16p13.11 15704492 15389
6 
Hs00358138_c
n 
NS 16074
5 
16444274 
MYH6 MYOSIN, HEAVY CHAIN 6, 
CARDIAC MUSCLE, ALPHA 
14q11.2 22921038 26284 
 
NS 16071
0 
15735645 
MYH7 MYOSIN, HEAVY CHAIN 7, 
CARDIAC MUSCLE, BETA 
14q11.2 22951786 22924 
 
NS 16076
0 
21604106, 
18159245 
NF1 NEUROFIBROMATOSIS, 
TYPE I 
17q11.2 26446120 28270
1 
 
S 16220
0 
11078559, 
20193066 
NKX2-5 NK2 HOMEOBOX 5 5q35.2 17259174
3 
3125 
 
NS 60058
4 
9651244 
NKX2-6 NK2, DROSOPHILA, 
HOMOLOG OF, 6 
8p21.1 23615909 3957 
 
NS 61177
0 
15649947 
NODAL NODAL, MOUSE, 
HOMOLOG OF 
10q22.1 71862076 9353 
 
NS 60126
5 
19064609 
NOTCH1 NOTCH, DROSOPHILA, 
HOMOLOG OF, 1 
9q34.3 13850871
6 
51343 Hs00041764_c
n 
NS 19019
8 
16025100, 
19597493 
NOTCH2 NOTCH, DROSOPHILA, 
HOMOLOG OF, 2 
1p12 12025569
8 
15810
1 
 
S 60027
5 
16773578 
NPHP3 NEPHROCYSTIN 3 3q22.1 13388214
3 
41823 Hs02580407_c
n 
S 60800
2 
19177160 
NRAS NEUROBLASTOMA RAS 
VIRAL ONCOGENE 
HOMOLOG 
1p13.2 11504860
0 
12438 
 
S 16479
0 
20193066 
NSD1 NUCLEAR RECEPTOR-
BINDING Su-var, 
ENHANCER OF ZESTE, 
AND TRITHORAX 
5q35.2–
5q35.3 
17649268
5 
16713
5 
Hs00053100_c
n 
S 60668
1 
15742365, 
20193066 
     
Hs00022652_c
n 
   
PDGFRA PLATELET-DERIVED 
GROWTH FACTOR 
RECEPTOR, ALPHA 
4q12 54790020 69149 
 
NS 17349
0 
20071345 
PITX2 PAIRED-LIKE 
HOMEODOMAIN 
TRANSCRIPTION FACTOR 
2 
4q25 11175802
8 
19929 
  
60154
2 
16274491 
PPM1K PROTEIN PHOSPHATASE, 
PP2C DOMAIN-
CONTAINING, 1K 
4q22.1 89400555 24357 
  
61106
5 
19597493 
PRKAB2 PROTEIN KINASE, AMP-
ACTIVATED, 
NONCATALYTIC, BETA-2 
1q21.1 14509330
8 
17445 Hs02605549_c
n 
 
60274
1 
15117819 
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Gene Gene Name Cytoban
d 
Gene 
Start 
Gene 
Size 
ABI CN Assay 
# 
CHD 
WIK
I 
OMIM 
ID 
PubMed 
ID 
PTPN11 PROTEIN-TYROSINE 
PHOSPHATASE, 
NONRECEPTOR-TYPE, 11 
12q24.13 11134091
8 
91182 
 
S 17687
6 
17515436 
RAB10 RAS-ASSOCIATED 
PROTEIN RAB10 
2p23.3 26110477 10330
5 
  
61267
2 
19597493 
RAF1 V-RAF-1 MURINE 
LEUKEMIA VIRAL 
ONCOGENE HOMOLOG 1 
3p25.1 12600099 80601 Hs02645733_c
n 
 
16476
0 
17603483, 
19597493 
RAI1 RETINOIC ACID-INDUCED 
GENE 1 
17p11.2 17525511 12997
9 
 
S 60764
2 
16845274, 
20193066 
ROR2 RECEPTOR TYROSINE 
KINASE-LIKE ORPHAN 
RECEPTOR 2 
9q22.31 93524704 22756
1 
 
S 60233
7 
20193066 
RUNX1 RUNT-RELATED 
TRANSCRIPTION FACTOR 
1 
21q22.12 35081967 26149
8 
  
15138
5 
19863549, 
19172993 
SALL4 SAL-LIKE 4 20q13.2 49833989 18466 Hs00139344_c
n 
S 60734
3 
12843316 
SEMA5A SEMAPHORIN 5A 5p15.2 9088137 51109
6 
Hs01709772_c
n 
 
60929
7 
9464278 
SH3PXD2
B 
SH3 AND PX DOMAINS-
CONTAINING PROTEIN 2B 
5q35.1 17169310
7 
12102
5 
 
S 61329
3 
20137777 
SHOC2 SUPPRESSOR OF CLEAR, 
C. ELEGANS, HOMOLOG 
OF 
10q25.2 11271390
2 
49511 
 
S 60277
5 
19684605, 
20193066 
SLC2A10 SOLUTE CARRIER FAMILY 
2 (FACILITATED GLUCOSE 
TRANSPORTER), MEMBER 
10 
20q13.12 44771685 26707 
 
S 60614
5 
16550171, 
20193066 
SOS1 SON OF SEVENLESS, 
DROSOPHILA, HOMOLOG 
1 
2p22.1 39062193 13891
5 
 
S 18253
0 
17143285 
SOX7 SRY-BOX 7 8p23.1 10618687 6745 Hs00923277_c
n 
 
61220
2 
19606479 
STRA6 STIMULATED BY 
RETINOIC ACID 6, 
MOUSE, HOMOLOG OF 
15q24.1 72258860 23385 Hs01994903_c
n 
S 61074
5 
17273977 
TBX1 T-BOX 1 22q11.21 18124225 26887 Hs01313390_c
n 
NS, 
S 
60205
4 
14585638 
TBX20 T-BOX 20 7p14.3 35208566 51201 Hs04957392_c
n 
NS 60606
1 
17668378, 
19762328 
TBX3 T-BOX 3 12q24.21 11359244
1 
13911 
 
S 60162
1 
16892408 
TBX5 T-BOX 5 12q24.21 11327611
7 
54513 
 
S 60162
0 
11376442 
TDGF1 TERATOCARCINOMA-
DERIVED GROWTH 
FACTOR 1 
3p21.31 46594183 4773 
 
NS 18739
5 
18538293, 
20193066 
TERT TELOMERASE REVERSE 
TRANSCRIPTASE 
5p15.33 1306286 41876 Hs03078158_c
n 
 
18727
0 
 
TFAP2B TRANSCRIPTION FACTOR 
AP2-BETA 
6p12.3 50894397 28888 Hs01355864_c
n 
NS, 
S 
60160
1 
10802654 
TGFBR2 TRANSFORMING GROWTH 
FACTOR-BETA RECEPTOR, 
TYPE II 
3p24.1 30622997 87640 
  
19018
2 
15235604, 
15731757 
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Gene Gene Name Cytoban
d 
Gene 
Start 
Gene 
Size 
ABI CN Assay 
# 
CHD 
WIK
I 
OMIM 
ID 
PubMed 
ID 
TMEM40 TRANSMEMBRANE 
PROTEIN 40 
3p25.1 12750391 25417 Hs01878707_c
n 
  
19597493 
VEGFA VASCULAR ENDOTHELIAL 
GROWTH FACTOR A 
6p21.1 43845930 16271 
 
NS 19224
0 
20420808 
WHSC1 WHS CANDIDATE 1 GENE 4p16.3 1842920 11081
2 
Hs02237093_c
n 
 
60295
2 
9222965 
ZEB2 ZINC FINGER E BOX-
BINDING HOMEOBOX 2 
2q22.3 14486205
2 
13233
4 
 
S 60580
2 
11595972 
ZFPM2 ZINC FINGER PROTEIN, 
MULTITYPE 2 
8q23.1 10640032
2 
48562
1 
 
NS 60369
3 
9927675, 
10892744 
ZIC3 ZINC FINGER PROTEIN OF 
CEREBELLUM 3 
Xq26.3 13647601
1 
5914 Hs02692150_c
n 
NS 30026
5 
14681828, 
10980576 
NS, nonsyndromic; S, syndromic, NCBI Build 36.1/hg18. 
**Animal study. 
CHD consists of heterogenous anatomy with distinct phenotypic 
subtypes. The European Paediatric Cardiac Coding (EPCC) System17 
has been cross mapped with the Society of Thoracic Surgeons/ 
European Association of Cardiothoracic Surgery (STS/EACTS) coding 
system through the International Society for Nomenclature of 
Paediatric and Congenital Heart Disease in the creation of the 
International Pediatric and Congenital Cardiac Code (IPCCC). We 
characterized cardiac malformations by subphenotyping according to 
both the EPCC and the STS/EACTS coding systems. We compared 945 
CHD cases with a publicly available cohort of 2,026 disease-free 
primarily pediatric individuals.40 Cases and controls were genotyped on 
different platforms; therefore, a second cohort of 880 control subjects 
genotyped on the same platform and within the same facility as the 
CHD cohort was included in the analysis. 
This study represents a quantitative analysis of CNVs in a large 
population of subjects with precisely phenotyped cardiac 
malformations involving 100 candidate CHD risk genes. We 
hypothesized that large rare CNVs that were statistically enriched 
against two control cohorts would be causal. A strict algorithm was 
employed to determine if subphenotypes were enriched in gains and 
losses within 100 recognized CHD risk genes selected based on gene 
content compared with two control cohorts. Finally, a novel analytical 
approach, permitting CNV gene frequency spectra to be computed as a 
proportion of each cohort containing a gain or a loss over the above 
prespecified regions, was employed to determine phenotype-gene 
dosage relationships. 
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Methods 
CHD Case Ascertainment and Confirmation 
This study was reviewed and approved in accordance to 
institutionally approved research [Institutional Review Board (IRB)] 
protocols by the Children's Hospital of Wisconsin (CHW, Milwaukee, 
WI). Subjects were consented through the Congenital Heart Disease 
Tissue Bank (CHDTB) and the Wisconsin Pediatric Cardiac Registry 
(WPCR), IRB-approved research databases housed at CHW.20,47 These 
two biobanks provide DNA samples from cases and family members, 
detailed maternal environmental exposure data, family history of CHD, 
and cardiac tissue discards. 
Inclusion criteria.  
Structural congenital cardiac abnormalities, as identified within 
the IPCCC, included abnormalities of the following: the atria and atrial 
septum; atrioventricular valves or atrioventricular septum; cardiac 
position and connections; chest wall; conduction system; coronary 
arteries, arterial duct, pericardium, or arteriovenous fistulae; great 
veins; ventricles or ventricular septum; and ventriculoarterial valves or 
great arteries. 
Exclusion criteria.  
All acquired forms of pediatric heart disease in the absence of 
CHD, and frequent nonpathologic structural variants when no other 
CHD is present, included: patent foramen ovale, patent ductus 
arteriosus (PDA) under 30 days of age, PDA in premature infants (<35 
wk gestation) and mitral valve prolapse (in the absence of at least 
mild valve insufficiency). 
Note: The presence of a known or suspected chromosomal 
abnormality or known sequence variant in a CHD risk gene did not 
preclude participation in the study. In addition, the presence or 
absence of known environmental exposures did not preclude 
participation in the study. 
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Anatomic cardiac malformations were carefully characterized by 
phenotyping and subphenotyping according to both the EPCC 2011 and 
the STS/EACTS 2011 coding systems. All phenotypes were initially 
reviewed by a coding specialist, a surgeon, and a cardiologist. All 
discrepancies were reconciled by review of source documents including 
operative notes, echocardiograms, and review of operative surgeon. 
Anatomic phenotypes and subphenotypes were reported using EPCC 
2011 terms, and final confirmatory review of all cases was performed 
by a single pediatric cardiothoracic surgeon.17 In addition, information 
regarding additional diagnosis, accompanying conditions, 
demographics, and a limited number of genetic risk factors was 
obtained through the Herma Heart Center (HHC) cardiac database at 
CHW. 
Children's Hospital of Philadelphia Control Cohort 
DNA samples analyzed in this study were obtained from the 
whole blood of healthy subjects routinely seen at primary care and 
well-child clinic practices within the Children's Hospital of Philadelphia 
(CHOP) Health Care Network. Data using hg18/March 2006/build 36.1 
genomic coordinates were downloaded from http://cnv.chop.edu/.40 
High-resolution mapping of copy number variations in 2,026 healthy 
individuals was performed using the Illumina HumanHap 550 BeadChip 
(Illumina, San Diego, CA).40 
Milwaukee Family Heart Study Control Cohort 
Control subjects were drawn from the Milwaukee Family Heart 
Study (MFHS) in accordance with Medical College of Wisconsin IRB 
protocols (MCW, Milwaukee, WI). Subjects were ascertained as a 
hospital-based cohort, referred to the catheterization laboratory for 
diagnostic coronary angiography. Inclusion criteria were the ability to 
consent and age >21 yr. The following were considered exclusion 
criteria: end-stage renal disease, current treatment for a malignancy, 
and a diagnosis of coronary artery disease or a myocardial infarction at 
age >69 yr. In addition, we excluded all participants with acute 
coronary syndrome and significant valvular disease. Individuals with a 
diagnosis of other cardiac structural abnormalities were excluded 
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based on either the result of echocardiography prior to or as 
determined during the invasive cardiac procedure. 
Genomic DNA Extraction 
Genomic DNA for CHD and MFHS cohorts was obtained from 
peripheral blood using standard protocols for DNA isolation from Roche 
Diagnostics, Promega Biotech (Wizard), and Qiagen (Gentra 
Puregene). Purified genomic DNA was resuspended in 1.0 mM Tris HCl 
pH 8.0 and 0.1 mM EDTA. DNA quality was tested by optical density 
260/280 ratios, quantified by UV spectrophotometry using a Nanodrop 
2000 (Thermo Scientific, Wilmington, DE). DNA stocks were stored at 
−80°C, dilutions for microarray analysis were stored at 100 ng/μl at 
−20°C. 
CHD Risk Gene Prioritization and Selection 
Genes or regions with previously associated disease/syndrome 
variants as identified through the CHD WIKI website (searched 
01/04/2011 and updated 07/28/2011) and/or supported by previously 
published observations in human studies were selected.1,34,36,42,48 
These known CHD risk genes are outlined in Table 1. 
Briefly, CHD WIKI offers an updated overview of genes 
implicated in human CHD, obtained by an OMIM search, and 
complemented with a study of the PubMed literature concerning 
mutation analysis of candidate genes for congenital heart defects.1 The 
level of support was defined by inheritance of the mutation (de novo 
or inherited and segregated with a phenotype) and the association of a 
variant in the investigated CHD population vs. a normal control 
population.1 A comprehensive list of 100 CHD risk genes was selected; 
the vast majority of these selected genes are known to be expressed 
in the human heart.3,11,43,46,50,54 According to CHD WIKI, syndromic 
genes were defined as congenital heart defects that are associated 
with a second major malformation (i.e., renal defects, cleft palate, 
brain malformations), with developmental delay or mental handicap, 
and/or the presence of dysmorphism. 
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Genotyping 
Genotyping for the CHD and MFHS control cohort was performed 
with the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, 
Santa Clara, CA) as previously described.30,47 All samples were run in 
the Advanced Genomics (AGEN) laboratory core at the Children's 
Research Institute (CRI)/MCW (Milwaukee, WI). A reference genomic 
DNA control sample, ref 103, supplied by Affymetrix, was run with 
every batch of subjects (Santa Clara, CA). 
CNV Analysis and Quality Control 
The CHD subject cohort comprised 1,020 subjects consented through 
the CHDTB or WPCR. We evaluated the quality and suitability of the 
subject population for a genetic association study. The population was 
required to pass copy number analysis quality metrics as seen in Table 
2. 
Table 2. Quality control of CHD case and MFHS control cohorts and 
genotyping data 
 Subjects, n  Subjects, n 
MFHS Control Cohort  CHD Case Cohort  
    Starting subjects 950     Starting subjects 1,020 
    Remaining subjects 880     Remaining subjects 958 
QC Exclusions % Total  % Total 
    MAPD QC 3.05 MAPD QC 2.35 
    Segment QC 4.32     Segment QC 2.15 
    Consent QC NA     Consent QC 0.10 
    Sex QC NA     Sex QC 0.59 
Copy number analysis exclusions were as follows: median absolute pairwise difference 
(MAPD) quality control (QC) ≥0.35, number of copy number polymorphism (CNP) 
segments ≥250, 1 subject with a status change to his/her consent, and sex tracking 
QC. Congenital heart disease (CHD) cases were reduced to a final n = 945 after 
inclusion and exclusion criteria were met. 
CNV identification of study subjects required the processing of 
Affymetrix intensity (CEL) files using Genotyping Console version 3.0.2 
(GTC) software as previously described.20,47 CEL files of subjects with a 
median absolute pairwise difference >0.35 and a CNV segmentation 
count ≥250, indicative of poor DNA quality, were excluded from the 
study. 
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A final number of 945 CHD subjects and 880 MFHS controls 
remained in the study after inclusion and exclusion criteria were met. 
As summarized in Table 3, the cases and controls were stratified 
according to age, sex, and race/ethnicity. 
Table 3. CHD case, CHOP, and MFHS control cohort demographics 
 CHD Case 
Cohort 
CHOP Control 
Cohort 
MFHS Control 
Cohort 
Race    
    Caucasian 655 1,320 870 
    African 
American 
92 694 5 
    Native 
American 
14  5 
    Hispanic 90   
    Asian 26 12  
    Other 68   
Total 945 2,026 880 
Sex, %    
    Female 44.02  36.59 
    Male 55.87  63.41 
Age, yr    
    Median age 0.62  67.00 
    Average age 4.03  65.66 
CHOP, Children's Hospital of Philadelphia ; MFHS, Milwaukee Family Heart Study. 
Copy number state of those subjects who passed quality control 
thresholds were determined with reference to the 
GenomeWideSNP_6.hapmap270 file and copy number calls were 
determined using the Affymetrix GTC segmentation algorithm. To 
reduce the presence of false positive CNVs, the segmentation 
algorithm parameters were set to identify only those regions larger 
than 25 kb comprising at least 25 contiguous markers. It has been 
shown that CNVs smaller than this are frequently false positive 
detection.40 In addition, all segments were monitored for degree of 
overlap with previously identified common CNVs, annotated by the 
DGV.22,57 
Using a BED file format (chromosome, gene starting position, 
gene ending position, gene name), copy number information was 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Physiological Genomics, Vol 44, No. 9 (May 1, 2012): pg. 518-541. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
16 
 
drawn from custom gene regions (Table 1) extracted from the 
processed segment data. 
A flowchart for copy number analysis is presented in Fig. 1. A 
multipurpose Access database (Microsoft, Redmond, WA) served as a 
central repository for the cohort demographic data as well as the 
entire experimental set of copy number variant data. Database tables 
were populated with copy number data from the GTC analysis, detailed 
demographic data, and the annotated 100 CHD risk gene list (Table 1). 
Demographic data for CHD cases and MFHS controls were obtained via 
clinical and consent verification methods. SQL query results included 
aggregate CNV counts by phenotype or region for both CHD and MFHS 
controls. Graphical representation of the query results was 
accomplished using Excel (Microsoft) and R.45 Supplemental Table S1 
includes a complete summary of all CNV profiles over the 100 CHD risk 
gene list for each subject as well as phenotypic and demographic 
information.1 
 
Fig. 1. CNV analysis flowchart from sample to statistics. Blue figures represent 
software used or a process/task performed. Red figures represent data files. 
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Overall CNV burden.  
The total number of large CNVs throughout the genome was 
calculated by importing GTC segment files filtered by size (duplication 
≥200 kb or deletion ≥100 kb) into an Access database. An external R 
program further filtered CNVs for all Build 36 annotated genes that did 
not occur as a CNP, defined as a normal variant (≥1%) in either the 
CHOP or MFHS control cohorts. 
Algorithm for likely causal CNV determination.  
A strict algorithm was employed to determine likely causal 
CNVs. Gains and losses were considered as potentially disease relevant 
if they fulfilled the following criteria: 1) size: duplication ≥200 kb or 
deletion ≥100 kb, 2) they did not occur as a CNP, defined as a normal 
variant (≥1%) in either CHOP or MHFS control cohort, and 3) CNV 
occurred over a gene region known to be associated with CHD (CHD 
100 gene list). 
A final step was taken because the MFHS cohort was aged and 
significantly different from CHD cases. Sex chromosome degradation in 
peripheral blood appears to be an age-related phenomenon.19 Studies 
have shown that a strong correlation exists between patient age and 
loss of the Y chromosome.52 Sex chromosome degradation is easily 
detected by the segment reports created by GTC because males have 
only one copy of Chr. X. To optimize the analysis of sex chromosomes, 
sex-matched references were employed; for X chromosome analysis, 
only females from all three cohorts were compared.55 Thus male MFHS 
controls were excluded from X chromosome results in all CNV 
analyses. 
CNV frequency by phenotype.  
CNVs fulfilling criteria 1–3 were analyzed for enrichment by 
subphenotypes. 
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CNV frequency by gene region.  
CNV frequency “spectra” were computed as a proportion of each 
cohort containing a gain or a loss over the CHD associated gene list. 
Complex CNV analysis.  
To determine if subjects carried multiple CNVs, large rare CNVs 
outside of and in addition to the defined set of 100 disease-related 
CHD genes were screened using criteria 1 and 2 (see Ref. 56). 
Confirmatory Studies 
CNVs that were identified in the CHD cases were confirmed by 
either karyotype, FISH analysis, or TaqMan CN real-time quantitative 
PCR assays (Applied Biosystems). CNVs for one case asterisked in 
Table 5 was difficult to confirm and is currently pending, due to 
inconclusive TaqMAN copy number results. A representative set of 
identified CNVs within the CHOP cohort were previously validated,40 
whereas CNVs identified in the MFHS cohort as part of this study were 
not confirmed. As a means of secondary CNV confirmation of CHD 
cases, microarray analysis was performed by an independent lab on a 
number of the CHD study subjects (n = 34). TaqMan copy number 
reactions (Table 1) were run in triplicate on an ABI HT7900 instrument 
(Applied Biosystems) under the following cycling conditions: 50°C for 2 
min, 95°C for 10 min, then 40 cycles of 95°C for 15 s followed by 
60°C for 1 min. Typically ∼20 ng of template genomic DNA was 
amplified in reaction volumes of 10 μl, as previously described.47 Copy 
number confirmations were assessed using a calibrator panel of six 
individuals with known copy number state over the gene of interest 
and analyzed using Copy Caller software version 1.0 (Applied 
Biosystems). If parents of subjects with confirmed CNVs were 
available, their DNA was analyzed to determine if CNVs were inherited 
or de novo, as noted in Table 5. 
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Table 5. Case reports of likely causal CNVs 
Subject Subphenotype 100 
CHD 
Gene 
Region 
Exon(s) LOSS_GAIN Cytoband CNV Start 
(Build 36, 
hg18) 
CNV 
Size, 
kb 
Markers, 
n 
Inheritance Gene 
Names on 
CNV 
Segment 
(100 CHD 
Genes in 
boldface) 
1 AS (valvar) ACP6 
BCL9 
CHD1L 
FMO5 
GJA5 
PRKAB2 
all Loss 1q21.1 144643813 1654 684 
 
NBPF11 
FAM108A3 
PRKAB2 
FMO5 
CHD1L 
BCL9 
ACP6 
GJA5 GJA8 
GPR89B 
NBPF11 
2 AS (valvar) CHD1L 
FMO5 
PRKAB2 
all Gain 1q21.1 144943150 418 280 
 
PRKAB2 
FMO5 
CHD1L 
  
NSD1 all Gain 5q35.2–
5q35.3 
175269980 1777 735 
 
THOC3 
FAM153B 
C5orf25 
KIAA1191 
ARL10 
HSPC111 
HIGD2A 
CLTB FAF2 
RNF44 
PCDH24 
GPRIN1 
SNCB 
EIF4E1B 
TSPAN17 
UNC5A 
HK3 UIMC1 
ZNF346 
FGFR4 
NSD1 
RAB24 
PRELID1 
MXD3 
LMAN2 
RGS14 
SLC34A1 
PFN3 F12 
GRK6 PRR7 
DBN1 
PDLIM7 
DOK3 
DDX41 
FLJ10404 
TMED9 
B4GALT7 
3 AS (valvar) FOXC1 all Loss 6p25.3–
6p25.2 
94649 2539 2130 
 
DUSP22 
IRF4 
EXOC2 
HUS1B 
FOXQ1 
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Subject Subphenotype 100 
CHD 
Gene 
Region 
Exon(s) LOSS_GAIN Cytoband CNV Start 
(Build 36, 
hg18) 
CNV 
Size, 
kb 
Markers, 
n 
Inheritance Gene 
Names on 
CNV 
Segment 
(100 CHD 
Genes in 
boldface) 
FOXF2 
FOXC1 
GMDS 
C6orf195 
MYLK4 
4 ASD-SEC MYH11 all Loss 16p13.11–
16p12.3 
15186307 2903 1521 
 
MPV17L 
C16orf45 
KIAA0430 
NDE1 
MYH11 
C16orf63 
ABCC1 
ABCC6 
NOMO3 
LOC339047 
XYLT1 
5 ASD-SV GATA4 all Loss 8p23.1 11390744 304 213 
 
BLK 
GATA4 
NEIL2 
6 AVC (partial) GATA4 
SOX7 
all Loss 8p23.1 8055434 3844 3235 
 
PRAGMIN 
CLDN23 
MFHAS1 
THEX1 
PPP1R3B 
TNKS 
MSRA 
UNQ9391 
RP1L1 
C8orf74 
SOX7 
PINX1 
XKR6 
MTMR9 
AMAC1L2 
FAM167A 
BLK 
GATA4 
NEIL2 
FDFT1 
CTSB CTSB 
DEFB137 
DEFB136 
DEFB134 
7 AVC (partial) GDF1 all Gain 19p13.11 18763592 378 163 
 
UPF1 
GDF1 
LASS1 
COPE 
DDX49 
HOMER3 
SFRS14 
ARMC6 
SLC25A42 
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Subject Subphenotype 100 
CHD 
Gene 
Region 
Exon(s) LOSS_GAIN Cytoband CNV Start 
(Build 36, 
hg18) 
CNV 
Size, 
kb 
Markers, 
n 
Inheritance Gene 
Names on 
CNV 
Segment 
(100 CHD 
Genes in 
boldface) 
TMEM161A 
MEF2B 
8 AVC unbalanced + 
AVSD with 
ventricular 
imbalance 
MID1 5′ UTR-
i1 
Gain Xp22.2 10714630 509 265 
 
MID1 
HCCS 
ARHGAP6 
AMELX 
9 AVSD with TOF CRKL 
TBX1 
all Gain 22q11.21 17953160 1838 1106 
 
SEPT5 
GP1BB 
TBX1 
GNB1L 
C22orf29 
TXNRD2 
COMT 
ARVCF 
C22orf25 
DGCR8 
HTF9C 
RANBP1 
ZDHHC8 
RTN4R 
DGCR6L 
RIMBP3 
ZNF74 
SCARF2 
KLHL22 
MED15 
PI4KA 
SERPIND1 
SNAP29 
CRKL 
AIFM3 
LZTR1 
THAP7 
P2RX6 
SLC7A4 
10 CoA ACP6 
BCL9 
CHD1L 
FMO5 
GJA5 
PRKAB2 
all Gain 1q21.1 144812585 1480 678 
 
PRKAB2 
FMO5 
CHD1L 
BCL9 
ACP6 
GJA5 GJA8 
GPR89B 
GPR89C 
NBPF11 
LOC728912 
11 CoA NOTCH1 all Loss 9q34.3 138377108 229 105 
 
DNLZ 
CARD9 
SNAPC4 
SDCCAG3 
PMPCA 
INPP5E 
SEC16A 
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Subject Subphenotype 100 
CHD 
Gene 
Region 
Exon(s) LOSS_GAIN Cytoband CNV Start 
(Build 36, 
hg18) 
CNV 
Size, 
kb 
Markers, 
n 
Inheritance Gene 
Names on 
CNV 
Segment 
(100 CHD 
Genes in 
boldface) 
C9orf163 
NO TCH1 
12 DILV HRAS all Gain 11p15.5 354390 256 62 
 
B4GALNT4 
PKP3 
SIGIRR 
TMEM16J 
PTDSS2 
RNH1 
HRAS 
LRRC56 
C11orf35 
RASSF7 
KIAA1542 
IRF7 
MUPCDH 
13 DORV SEMA5A i8-3′ 
UTR 
Gain 5p15.31–
5p15.2 
7119715 2152 1769 
 
ADCY2 
C5orf49 
FASTKD3 
MTRR 
SEMA5A 
14 EBSTEIN'S FKBP6 5′ UTR-
i8 
Gain 7q11.23 72073034 330 28 
 
TRIM74 
STAG3L3 
NSUN5 
TRIM50 
FKBP6 
15 HLHS EHMT1 all Gain 9q34.3 139701521 264 142 
 
EHMT1 
CACNA1B 
16 HLHS FKBP6 5′ UTR-
i8 
Gain 7q11.23 72052197 348 34 de novo POM121 
NSUN5C 
TRIM74 ST 
AG3L3 
NSUN5 
TRIM50 
FKBP6 
17 HLHS GATA4 all Gain 8p23.1 11049252 1438 755 unknown XKR6 
MTMR9 
AMAC1L2 
FAM167A 
BLK 
GATA4 
NEIL2 
FDFT1 
CTSB 
DEFB137 
DEFB136 
DEFB134 
DEFB130 
ZNF705D 
DUB3 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Physiological Genomics, Vol 44, No. 9 (May 1, 2012): pg. 518-541. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
23 
 
Subject Subphenotype 100 
CHD 
Gene 
Region 
Exon(s) LOSS_GAIN Cytoband CNV Start 
(Build 36, 
hg18) 
CNV 
Size, 
kb 
Markers, 
n 
Inheritance Gene 
Names on 
CNV 
Segment 
(100 CHD 
Genes in 
boldface) 
FAM86B1 
DEFB130 
  
SOX7 all Gain 8p23.1 8055434 2992 2584 unknown PRAGMIN 
CLDN23 
MFHAS1 
THEX1 
PPP1R3B 
TNKS 
MSRA 
UNQ9391 
RP1L1 
C8orf74 
SOX7 
PINX1 
XKR6 
18 HLHS MYH11 all Gain 16p13.11 14846829 1414 640 inherited NOMO1 
NPIP 
PDXDC1 
NTAN1 
RRN3 
MPV17L 
C16orf45 
KIAA0430 
NDE1 
MYH11 
C16orf63 
ABCC1 
ABCC6 
NOMO3 
19 Other, Cardiac CRKL 
TBX1 
all Gain 22q11.21 17161534 2634 1575 
 
DGCR6 
PRODH 
DGCR2 
DGCR14 
TSSK2 
GSC2 
SLC25A1 
CLTCL1 
HIRA 
MRPL40 
C22orf39 
UFD1L 
CDC45L 
CLDN5 
SEPT5 
GP1BB 
TBX1 
GNB1L 
C22orf29 
TXNRD2 
COMT 
ARVCF 
C22orf25 
DGCR8 
HTF9C 
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Subject Subphenotype 100 
CHD 
Gene 
Region 
Exon(s) LOSS_GAIN Cytoband CNV Start 
(Build 36, 
hg18) 
CNV 
Size, 
kb 
Markers, 
n 
Inheritance Gene 
Names on 
CNV 
Segment 
(100 CHD 
Genes in 
boldface) 
RANBP1 
ZDHHC8 
RTN4R 
DGCR6L 
RIMBP3 
ZNF74 
SCARF2 
KLHL22 
MED15 
PI4KA 
SERPIND1 
SNAP29 
CRKL 
AIFM3 
LZTR1 
THAP7 
P2RX6 
SLC7A4 
20 PA, VSD ACP6 
BCL9 
CHD1L 
FMO5 
GJA5 
PRKAB2 
all Gain 1q21.1 144812585 1480 678 
 
PRKAB2 
FMO5 
CHD1L 
BCL9 
ACP6 
GJA5 GJA8 
GPR89B 
GPR89C 
NBPF11 
LOC728912 
21 Subaortic stenosis CRKL all Gain 22q11.21 19093207 699 626 
 
ZNF74 
SCARF2 
KLHL22 
MED15 
PI4KA 
SERPIND1 
SNAP29 
CRKL 
AIFM3 
LZTR1 
THAP7 
P2RX6 
SLC7A4 
22 Subaortic stenosis HRAS all Gain 11p15.5 339238 271 63 
 
B4GALNT4 
PKP3 
SIGIRR 
TMEM16J 
PTDSS2 
RNH1 
HRAS 
LRRC56 
C11orf35 
RASSF7 
KIAA1542 
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Subject Subphenotype 100 
CHD 
Gene 
Region 
Exon(s) LOSS_GAIN Cytoband CNV Start 
(Build 36, 
hg18) 
CNV 
Size, 
kb 
Markers, 
n 
Inheritance Gene 
Names on 
CNV 
Segment 
(100 CHD 
Genes in 
boldface) 
IRF7 
MUPCDH 
23 DORV FOXL2 
NPHP3 
all Gain 3q22.1–
3q26.1 
131972967 32134 19750 
 
PIK3R4 
ATP2C1 
ATP2C1 
ASTE1 
NEK11 
NUDT16 
MRPL3 
CPNE4 
ACPP 
DNAJC13 
ACAD11 
CCRL1 
UBA5 
NPHP3 
TMEM108 
BFSP2 
CDV3 
TOPBP1 TF 
SRPRB 
RAB6B 
          
C3orf36 
SLCO2A1 
RYK 
AMOTL2 
ANAPC13 
CEP63 KY 
EPHB1 
PPP2R3A 
MSL2L1 
PCCB ST 
AG1 
TMEM22 
NCK1 
IL20RB 
SOX14 
CLDN18 
DZIP1L 
A4GNT 
DBR1 
ARMC8 
TXNDC6 
MRAS 
FAM62C 
CEP70 
FAIM 
PIK3CB 
FOXL2 
C3orf72 
LOC389151 
MRPS22 
COPB2 
RBP2 RBP1 
NMNAT3 
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Subject Subphenotype 100 
CHD 
Gene 
Region 
Exon(s) LOSS_GAIN Cytoband CNV Start 
(Build 36, 
hg18) 
CNV 
Size, 
kb 
Markers, 
n 
Inheritance Gene 
Names on 
CNV 
Segment 
(100 CHD 
Genes in 
boldface) 
CLSTN2 
TRIM42 
SLC25A36 
SPSB4 
ACPL2 
ZBTB38 
RASA2 
RNF7 GRK7 
ATP1B3 
TFDP2 GK5 
XRN1 ATR 
PLS1 
TRPC1 
PCOLCE2 
PAQR9 
SR140 
CHST2 
SLC9A9 
C3orf58 
PLOD2 
PLSCR4 
PLSCR2 
PLSCR1 
PLSCR5 
ZIC4 ZIC1 
AGTR1 
CPB1 CPA3 
GYG1 HLTF 
HPS3 CP 
TM4SF18 
TM4SF1 
TM4SF4 
WWTR1 
COMMD2 
RNF13 
RNF13 
PFN2 
TSC22D2 
SERP1 
EIF2A SELT 
C3orf44 
SIAH2 
CLRN1 
CLRN1 
MED12L 
GPR171 
P2RY14 
GPR87 
P2RY13 
P2RY13 
P2RY12 
IGSF10 
AADACL2 
AADAC 
SUCNR1 
MBNL1 
TMEM14E 
P2RY1 
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Subject Subphenotype 100 
CHD 
Gene 
Region 
Exon(s) LOSS_GAIN Cytoband CNV Start 
(Build 36, 
hg18) 
CNV 
Size, 
kb 
Markers, 
n 
Inheritance Gene 
Names on 
CNV 
Segment 
(100 CHD 
Genes in 
boldface) 
RAP2B 
LOC152118 
SGEF 
DHX36 
GPR149 
MME 
PLCH1 
C3orf33 
SLC33A1 
GMPS 
KCNAB1 
SSR3 
TIPARP 
LEKR1 
CCNL1 
VEPH1 
PTX3 
C3orf55 
SHOX2 
RSRC1 
MLF1 GFM1 
LXN 
RARRES1 
MFSD1 
IQCJ 
SCHIP1 
IL12A 
IFT80 
SMC4 
TRIM59 
KPNA4 
ARL14 
PPM1L 
B3GALNT1 
NMD3 
C3orf57 
OTOL1 SI 
SLITRK3 
BCHE 
ZBBX 
SERPINI2 
WDR49 
PDCD10 
SERPINI1 
GOLIM4 
EVI1 EVI1 
MDS1 
ARPM1 
MYNN 
LRRC34 
LRRIQ4 
LRRC31 
SAMD7 
SEC62 
GPR160 
PHC3 
PRKCI SKIL 
CLDN11 
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Subject Subphenotype 100 
CHD 
Gene 
Region 
Exon(s) LOSS_GAIN Cytoband CNV Start 
(Build 36, 
hg18) 
CNV 
Size, 
kb 
Markers, 
n 
Inheritance Gene 
Names on 
CNV 
Segment 
(100 CHD 
Genes in 
boldface) 
SLC7A14 
RPL22L1 
EIF5A2 
SLC2A2 
TNIK PLD1 
FNDC3B 
GHSR 
TNFSF10 
AADACL1 
ECT2 
SPATA16 
NLGN1 
NAALADL2 
TBL1XR1 
KCNMB2 
ZMAT3 
PIK3CA 
KCNMB3 
ZNF639 
MFN1 
GNB4 
ACTL6A 
MRPL47 
NDUFB5 
USP13 
PEX5L 
TTC14 
CCDC39 
FXR1 
DNAJC19 
SOX2 
ATP11B 
DCUN1D1 
MCCC1 
LAMP3 
MCF2L2 
B3GNT5 
KLHL6 
KLHL24 
YEATS2 
MAP6D1 
PARL 
ABCC5 
HTR3D 
HTR3C 
HTR3E 
          
EIF2B5 
DVL3 
AP2M1 
ABCF3 
ALG3 ECE2 
CAMK2N2 
ECE2 
PSMD2 
EIF4G1 
FAM131A 
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Subject Subphenotype 100 
CHD 
Gene 
Region 
Exon(s) LOSS_GAIN Cytoband CNV Start 
(Build 36, 
hg18) 
CNV 
Size, 
kb 
Markers, 
n 
Inheritance Gene 
Names on 
CNV 
Segment 
(100 CHD 
Genes in 
boldface) 
CLCN2 
POLR2H 
THPO 
CHRD 
EPHB3 
MAGEF1 
VPS8 
C3orf70 
EHHADH 
MAP3K13 
TMEM41A 
LIPH 
SENP2 
IGF2BP2 
C3orf65 
SFRS10 
ETV5 
DGKG 
CRYGS 
TBCCD1 
DNAJB11 
AHSG 
FETUB HRG 
KNG1 
EIF4A2 
RFC4 
ADIPOQ 
ST6GAL1 
RPL39L 
RTP1 
MASP1 
RTP4 SST 
RTP2 BCL6 
LPP TPRG1 
TP63 
LEPREL1 
SENP2 
IGF2BP2 
C3orf65 
SFRS10 
ETV5 
DGKG 
CRYGS 
TBCCD1 
DNAJB11 
AHSG 
FETUB HRG 
KNG1 
EIF4A2 
RFC4 
ADIPOQ 
ST6GAL1 
RPL39L 
RTP1 
MASP1 
RTP4 SST 
RTP2 BCL6 
LPP TPRG1 
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Subject Subphenotype 100 
CHD 
Gene 
Region 
Exon(s) LOSS_GAIN Cytoband CNV Start 
(Build 36, 
hg18) 
CNV 
Size, 
kb 
Markers, 
n 
Inheritance Gene 
Names on 
CNV 
Segment 
(100 CHD 
Genes in 
boldface) 
TP63 
LEPREL1 
24 TOF ACP6 
BCL9 
GJA5 
all Gain 1q21.1 145250193 1678 471 
 
BCL9 
ACP6 
GJA5 GJA8 
GPR89B 
GPR89C 
NBPF11 
LOC728912 
PPIAL4 
NBPF14 
NBPF10 
NBPF15 
NBPF16 
  
CHD1L 
FMO5 
PRKAB2 
all Gain 1q21.1 144643813 600 223 
 
NBPF11 
LOC728912 
FAM108A3 
PRKAB2 
FMO5 
CHD1L 
25 TOF CRKL all Loss 22q11.21 18710744 1085 673 
 
RIMBP3 
ZNF74 
SCARF2 
KLHL22 
MED15 
PI4KA 
SERPIND1 
SNAP29 
CRKL 
AIFM3 
LZTR1 
THAP7 
P2RX6 
SLC7A4 
26 TOF HOXA1 all Gain 7p15.2–
7p15.1 
26113744 4718 3324 
 
NFE2L3 
HNRNP 
A2B1 CBX3 
SNX10 
SKAP2 
HOXA1 
HOXA2 
HOXA3 
HOXA4 
HOXA5 
HOXA6 
HOXA7 
HOXA9 
HOXA10 
HOXA11 
HOXA13 
EVX1 
HIBADH 
TAX1BP1 
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Subject Subphenotype 100 
CHD 
Gene 
Region 
Exon(s) LOSS_GAIN Cytoband CNV Start 
(Build 36, 
hg18) 
CNV 
Size, 
kb 
Markers, 
n 
Inheritance Gene 
Names on 
CNV 
Segment 
(100 CHD 
Genes in 
boldface) 
JAZF1 
LOC402644 
CREB5 
KIAA0644 
CPVL CHN2 
PRR15 
WIPF3 
SCRN1 
FKBP14 
PLEKHA8 
C7orf41 
ZNRF2 
NOD1 
C7orf24 
GARS 
CRHR2 
INMT 
FLJ22374 
  
TBX20 all Gain 7p14.3–
7p14.2 
32897122 3321 2145 
 
KBTBD2 
FKBP9 
NT5C3 RP9 
BBS9 
BMPER 
NPSR1 
DPY19L1 
TBX20 
HERPUD2 
SEPT7 
EEPD1 
27 TOF MYH11 all Gain 16p13.11 14805290 1455 642 
 
NOMO1 
NPIP 
PDXDC1 
NTAN1 
RRN3 
MPV17L 
C16orf45 
KIAA0430 
NDE1 
MYH11 
C16orf63 
ABCC1 
ABCC6 
NOMO3 
28* TOF TERT all Loss 5p15.33 80069 2948 1893 
 
PLEKHG4B 
LOC389257 
CCDC127 
SDHA 
PDCD6 
LOC116349 
EXOC3 
SLC9A3 
CEP72 
TPPP 
ZDHHC11 
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Subject Subphenotype 100 
CHD 
Gene 
Region 
Exon(s) LOSS_GAIN Cytoband CNV Start 
(Build 36, 
hg18) 
CNV 
Size, 
kb 
Markers, 
n 
Inheritance Gene 
Names on 
CNV 
Segment 
(100 CHD 
Genes in 
boldface) 
BRD9 
TRIP13 
NKD2 
SLC12A7 
SLC6A19 
SLC6A18 
TERT 
CLPTM1L 
SLC6A3 
LPCAT1 
MRPL36 
NDUFS6 
IRX4 IRX2 
C5orf38 
29 TRI-AT MAPK1 all Gain 22q11.21–
22q11.22 
20264556 447 243 
 
UBE2L3 
YDJC 
CCDC116 
SDF2L1 
PPIL2 
YPEL1 
MAPK1 
PPM1F 
TOP3B 
30 TRI-AT NSD1 e24-3′ 
UTR 
Gain 5q35.3 176656286 330 133 
 
NSD1 
RAB24 
PRELID1 
MXD3 
LMAN2 
RGS14 
SLC34A1 
PFN3 F12 
GRK6 PRR7 
DBN1 
PDLIM7 
DOK3 
DDX41 
FLJ10404 
TMED9 
B4GALT7 
31 Truncus arteriosus MAPK1 all Loss 22q11.21–
22q11.22 
20055986 1237 863 
 
HIC2 
RIMBP3B 
RIMBP3C 
UBE2L3 
YDJC 
CCDC116 
SDF2L1 
PPIL2 
YPEL1 
MAPK1 
PPM1F 
TOP3B 
VPREB1 
ZNF280B 
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Subject Subphenotype 100 
CHD 
Gene 
Region 
Exon(s) LOSS_GAIN Cytoband CNV Start 
(Build 36, 
hg18) 
CNV 
Size, 
kb 
Markers, 
n 
Inheritance Gene 
Names on 
CNV 
Segment 
(100 CHD 
Genes in 
boldface) 
ZNF280A 
PRAME 
  
GATA6 all Gain 18q11.2 17749666 308 168 
 
GATA6 
32 Truncus arteriosus SALL4 all Loss 20q13.2 49428074 1839 1357 
 
NFATC2 
ATP9A 
SALL4 
ZFP64 
TSHZ2 
33 VSD 
(perimembranous) 
CRKL all Gain 22q11.21 19389671 406 451 
 
PI4KA 
SERPIND1 
SNAP29 
CRKL 
AIFM3 
LZTR1 
THAP7 
P2RX6 
SLC7A4 
  
ACP6 
BCL9 
CHD1L 
FMO5 
GJA5 
PRKAB2 
all Loss 1q21.1 144723763 1574 683 
 
NBPF11 
LOC728912 
FAM108A3 
PRKAB2 
FMO5 
CHD1L 
BCL9 
ACP6 
GJA5 GJA8 
GPR89B 
GPR89C 
NBPF11 
34 VSD 
(perimembranous) 
GATA4 
SOX7 
all Loss 8p23.1 8027361 4456 3349 
 
PRAGMIN 
CLDN23 
MFHAS1 
THEX1 
PPP1R3B 
TNKS 
MSRA 
UNQ9391 
RP1L1 
C8orf74 
SOX7 
PINX1 
XKR6 
MTMR9 
AMAC1L2 
FAM167A 
BLK 
GATA4 
NEIL2 
FDFT1 
CTSB CTSB 
DEFB137 
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Subject Subphenotype 100 
CHD 
Gene 
Region 
Exon(s) LOSS_GAIN Cytoband CNV Start 
(Build 36, 
hg18) 
CNV 
Size, 
kb 
Markers, 
n 
Inheritance Gene 
Names on 
CNV 
Segment 
(100 CHD 
Genes in 
boldface) 
DEFB136 
DEFB134 
DEFB130 
ZNF705D 
DUB3 
FAM86B1 
DEFB130 
*Inconclusive TAQMAN results (see Subject 28). Boldface indicates confirmed genes. 
“Unknown” means one parental DNA was unavailable. “Other cardiac” phenotype (case 
19) is double-chamber right ventricle (DCRV). 
Statistical Analysis 
Since the expected incidence is very small (typically <5%) tests 
based on a normality assumption would be incorrect, therefore a one-
tailed Barnard exact test was used for all comparisons of proportions 
of CNVs.8 A P ≤ 0.05 without adjustment is used for significance. A 
custom R program was used to calculate the P value and checked 
using Cytel StatXact (Cytel, Cambridge, MA).15 StatXact was also used 
to calculate power. With a sample of 810, and a CNV incidence of 
4.3%, we would have at least 90% power to detect a significant 
difference from 0.0196 (the CNV incidence of CHOP cohort's 
39/2,026). We have given other power calculations for possible 
scenarios of subphenotypes (Fig. 2). We see that in an n = 100 sample 
group we would have ≥80% power if we had an 8% CNV incidence. 
For a cohort of 200 we would have ≥80% power to detect a difference 
of 6% CNV incidence. 
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Fig. 2. Sample size (n) and copy number variant (CNV) proportion (fraction), required 
to detect difference from 0.0196 (CHOP control CNV fraction) at an alpha = 0.05, 
power at least 80%. CHOP, Children's Hospital of Philadelphia. 
This figure demonstrates the sample size required (x-axis) with 
power of at least 80% under varying CNV proportions (y-axis) when 
the control cohort is 0.0196 (CHOP control CNV proportion) at an 
alpha = 0.05. 
Results 
Phenotypes of CHD Study Subjects 
Subjects diagnosed with congenital heart malformations (n = 
945) and phenotyped in accordance with the EPCC terms were 
categorized into the 40 cardiac subphenotypes listed in Table 4 (17). 
The five largest phenotypes represented were as follows: hypoplastic 
left heart syndrome (HLHS) 14.8%, ventricular septal defect (VSD 
perimembranous) 7.7%, tetralogy of Fallot (TOF) 7.7%, coarctation of 
the aorta (CoA) 7.0%, and atrioventricular canal complete (AVC 
complete) 5.0%. The majority of subjects were represented by 
individual subphenotypes most of which contained <5.1% of the total 
CHD cohort. 
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Table 4. CHD cohort by subphenotypes 
Diagnoses Subjects % of 
Total 
Diagnoses Subjects % of 
Total 
Aorto-pulmonary window + 
Patent Ductus Arteriosus 
(PDA)T21 
5 0.53 Mitral Valve Stenosis (MS, 
subvalvar, parachute)22q 
6 0.63 
AVSD + TOF (AVSD + TOF)T21 7 0.74 Other, CardiacT21, 22q 18 1.90 
Arrhythmias (Congenital 
Heart Block, Long QT, WPW) 
7 0.74 Pulmonary Atresia (PA) 
  
Aortic Stenosis (Valvar)T 31 3.28 - IVS-T21 18 1.90 
Atrial Septal Defect 
Secundum (ASD-SEC)T21 
47 4.97 - VSD-22q 34 3.60 
Atrial Septal Defect Sinus 
Venosus (ASD-SV) 
13 1.38 PAPVR 12 1.27 
A-V Canal Complete (AVC 
Complete)T21 
48 5.08 Pulmonary Stenosis (Valvar) 9 0.95 
A-V Canal Intermediate (AVC 
Intermediate)T21 
7 0.74 Shone's 8 0.85 
A-V Canal Partial (AVC 
Partial)T21 
17 1.80 Subaortic stenosisT21 12 1.27 
A-V Canal Unbalanced + 
AVSD with ventricular 
imbalanceT21 
14 1.48 Supravalvar aortic stenosis 
(supravalvar AS) 
4 0.42 
Cardiomyopathy (DILATED) 13 1.38 Total Anomalous Venous 
Connection (TAPVC) 
15 1.59 
Cardiomyopathy 
(HYPERTROPHIC) 
4 0.42 Tetralogy of Fallot (TOF)T21, 
22q 
73 7.72 
Chest Wall 4 0.42 Transposition of Great 
Arteries (TGA) 
  
Coarctation of the Aorta 
(CoA)T 
66 6.98 - IVS - 21 2.22 
Coronary Arteries (COR ART) 10 1.06 - VSD - 21 2.22 
Double Inlet Left Ventricle 
(DILV) 
19 2.01 Tricuspid Atresia (TRI-AT) 29 3.07 
Double Outlet Right Ventricle 
(DORV)22q 
41 4.34 Truncus Arteriosus (TA)22q 29 3.07 
Ebstein's Anomaly 
(EBSTEINS) 
9 0.95 Vascular ring and PA slingT21, 
22q 
14 1.48 
Hypoplastic Left Heart 
Syndrome (HLHS)T 
140 14.81 VSD inletT21 4 0.42 
Interrupted Aortic Arch 
(IAA)22q 
11 1.16 VSD multiple + muscular 10 1.06 
L-TGA 7 0.74 VSD perimembranousT21, 22q 73 7.72 
Dilated Ascending Aorta 
(MARFAN) 
8 0.85 VSD subarterialT21 7 0.74 
The following individual phenotypes were included in the “other cardiac” subphenotype 
category: single ventricle other, absent left pulmonary artery (LPA), absent pulmonary 
valve, aorto-left ventricular tunnel, bicuspid aortic valve (BAV), cor triatriatum, 
double-chamber right ventricle (DCRV), left ventricular aneurysm, tricuspid 
regurgitation, true cleft of mitral leaflet (without AVSD). Superscripts were used to 
denote phenotypes where causal chromosomal as shown abnormalities were observed 
(see results, where T21 = Trisomy 21, 22q = 22qDS, and T = Turner's Syndrome). 
PAPVR, partial anomalous pulmonary venous return; VSD, ventricular septal defect. 
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Subjects With Recognized Causal Chromosomal 
Abnormalities 
We ascribed 135 subjects to known CHD-related chromosomal 
abnormalities [T21 (n = 80), T18 (n = 1), 22qDS (n = 42), Turner (n 
= 8), William's (n = 3), and XXX (n = 1)].36,44 The syndromes and 
their associated phenotypes were as follows: T21: aorto-pulmonary 
window with PDA n = 2; AVSD + TOF n = 5; ASD-SEC n = 4; AVC 
complete n = 35; AVC intermediate n = 5; AVC partial n = 2; AVC 
unbalanced + AVSD with ventricular imbalance n = 1; other cardiac n 
= 1; pulmonary atresia (PA), IVS n = 1; subaortic stenosis n = 1; TOF 
n = 6; vascular ring + PA sling n = 1; VSD (inlet) n = 2; VSD 
(perimembranous) n = 13 and VSD (subarterial) n = 1, T18: TOF n = 
1, 22qDS: DORV n = 1; IAA n = 4; mitral stenosis, subvalvar, 
parachute + mitral stenosis n = 1; other cardiac n = 1; PA, VSD n = 
10; TOF n = 9; truncus arteriosus n = 12; vascular ring + PA sling n = 
1 and VSD (perimembranous) n = 3, Turner: aortic stenosis (valvar) n 
= 1; CoA n = 4 and HLHS n = 2, mosaic Turner: CoA n = 1, William's: 
supravalvar aortic stenosis and XXX: PA, IVS. 
Overall CNV Burden 
The total number of large CNVs (≥100 kb loss, ≥200 kb gain) 
throughout the genome were similar in both CHD and MFHS cohorts. 
When subjects with chromosomal abnormalities such as Trisomy 21 
and 18, Turner, 22qDS, William's, and XXX were excluded, a 
significant number of the CHD cohort, 567 out of 810, carried a large 
rare CNV over a gene somewhere in their genome, while in the MFHS 
control cohort, this number was 391 of 880. Gains were twofold more 
common than losses in both cohorts despite the requirement to be 
twice as long (Fig. 3). 
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Fig. 3. Total CNV burden by cohort. Standard box-and-whiskers plot for the 
distribution of large rare CNV segment count per subject in each of 4 cases: congenital 
heart disease (CHD) vs. Milwaukee Family Heart Study (MFHS) and gains vs. losses. 
Boxes represent the 1st and 3rd quartiles of each distribution, thick horizontal lines 
represent the median value, circles represent outliers, or the CHD cohort, major 
syndromes would significantly skew the distribution, so those subjects were excluded, 
leaving 810 syndrome-free subjects. Trisomy 21 and 18, Turner, 22qDS, William's and 
XXX chromosomal abnormalities were therefore excluded. 
CHD Case Reports 
Likely etiologic large, rare CNVs were identified in 35 CHD 
subjects. Table 5 summarizes the complete list of CHD subjects with 
CNVs over the known CHD risk gene regions (excluding the 135 
subjects with known CHD-related chromosomal abnormalities). Three 
HLHS subjects (cases 16, 17, and 18) were studied for inheritance, a 
gain over FKBP6 was found to be a de novo event, a gain involving 
GATA4 and SOX7 was not present in one parent and the status of the 
other parent was unknown, and the MYH11 gain was inherited. Table 5 
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reports all of the known genes within each CNV segment, including our 
selected 100 CHD-associated genes. 
Statistical Analysis of CNVs 
Subphenotype analysis.  
The CHD cohort, even after excluding genes involved in the 
known CHD-related chromosomal abnormalities, was enriched in large, 
rare CNVs involving CHD risk genes, where 35 of 810 subjects carried 
such a CNV (P ≤ 0.05 vs. both CHOP with 39 of 2,026 and MFHS with 
14 of 880). Breaking this cohort into subgroups by specific phenotype 
often resulted in groups too small for statistical significance. Different 
subdivision schemes may achieve nominal significance. The entries in 
Table 6 where the frequency of CNV was significantly (P ≤ 0.05) 
different from the CHOP and MFHS cohorts are marked with a double 
asterisk. The CHD cohort, after excluding known causal chromosomal 
abnormalities, showed a frequency of CNV at 4.3%, and a power 
calculation is performed in Fig. 2 showing the difficulty in detecting a 
difference from the control's 1.9%. For subgroups of 10–25 
individuals, the power to detect a difference from 1.9% (CHOP) 
required a proportion of 30 and 17%, respectively. Phenotypes 
showing significant (P ≤ 0.05) enrichment of large CNV events were 
aortic stenosis (valvar), AV canal (partial), AVSD with TOF, subaortic 
stenosis, TOF, and truncus arteriosus. Although HLHS was the most 
common phenotype in the CHD case cohort, this phenotype did not 
demonstrate significant large rare CNV enrichment. 
Table 6. CNV frequency by subphenotype 
 
Totals Including Causal 
Chromosomal Abnormalities 
 
Totals Excluding Causal 
Chromosomal Abnormalities 
 
Phenotype/Subphenotype Subjects Subjects 
with 
CNV 
Loss 
Subjects 
with 
CNV 
Gain 
Subjects 
with 
CNV 
Loss or 
Gain 
Subjects Subjects 
with 
CNV 
Loss 
Subjects 
with 
CNV 
Gain 
Subjects 
with 
CNV 
Loss or 
Gain 
CHOP Cohort 2,026 19 (0.94) 20 (0.99) 39 (1.92) 2,026 19 (0.94) 20 (0.99) 39 (1.92) 
MFHS Cohort 880 3 (0.34) 11 (1.25) 14 (1.59) 880 3 (0.34) 11 (1.25) 14 (1.59) 
CHD Cohort 945 66 (6.98) 110 
(11.64) 
172 
(18.20)** 
810 12 (1.48) 23 (2.84) 35 
(4.32)** 
    Turner 8 8 (0.84) 1 (0.10) 8 
    
    Trisomy18 (T18) 1 0 (0.00) 1 (0.10) 1 
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Totals Including Causal 
Chromosomal Abnormalities 
 
Totals Excluding Causal 
Chromosomal Abnormalities 
 
Phenotype/Subphenotype Subjects Subjects 
with 
CNV 
Loss 
Subjects 
with 
CNV 
Gain 
Subjects 
with 
CNV 
Loss or 
Gain 
Subjects Subjects 
with 
CNV 
Loss 
Subjects 
with 
CNV 
Gain 
Subjects 
with 
CNV 
Loss or 
Gain 
    Trisomy21 (T21) 80 0 (0.00) 80 (8.35) 80 
    
    Williams 3 3 (0.31) 0 (0.00) 3 
    
    XXX 1 0 (0.00) 1 (0.10) 1 
    
    22qDS 42 42 (4.38) 1 (0.10) 42 
    
Aorto-pulmonary window + PDA 5 0 (0.00) 2 (40.00) 2 
(40.00)** 
3 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 2 
  
2 2 
   
    22qDS 0 
   
0 
   
AVSD + TOF (AVSD + TOF) 7 0 (0.00) 6 (85.71) 6 
(85.71)** 
2 0 (0.00) 1 (50.00) 1 
(50.00)** 
    Trisomy21 5 
 
5 5 
    
    22qDS 0 
  
0 
    
Aortic Stenosis (Valvar) 31 3 (9.68) 1 (3.23) 4 
(12.90)** 
30 2 (6.67) 1 (3.33) 3 
(10.00)** 
    Turner 1 1 
 
1 
    
    Trisomy21 0 
  
0 
    
    22qDS 0 
  
0 
    
Atrial Septal Defect Secundum 
(ASD-SEC) 
47 1 (2.13) 4 (8.51) 5 
(10.64)** 
43 1 (2.33) 0 (0.00) 1 (2.33) 
    Trisomy21 4 
 
4 4 
    
    22qDS 0 
  
0 
    
Atrial Septal Defect Sinus 
Venosus (ASD-SV) 
13 1 (7.69) 0 (0.00) 1 (7.69) 13 1 (7.69) 0 (0.00) 1 (7.69) 
    Trisomy21 0 
  
0 
    
    22qDS 0 
  
0 
    
A-V Canal Complete (AVC 
Complete) 
48 0 (0.00) 35 
(72.92) 
35 
(72.92)** 
13 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 35 
 
35 35 
    
    22qDS 0 
  
0 
    
A-V Canal Intermediate (AVC     
Intermediate) 
7 0 (0.00) 5 (71.43) 5 
(71.43)** 
2 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 5 
 
5 5 
    
    22qDS 0 
  
0 
    
A-V Canal Partial (AVC Partial) 17 1 (5.88) 3 (17.65) 4 
(23.53)** 
15 1 (6.67) 1 (6.67) 2 
(13.33)** 
    Trisomy21 2 
 
2 2 
    
    22qDS 0 
  
0 
    
A-V Canal Unbalanced + AVSD 
with ventricular imbalance 
14 0 (0.00) 2 (14.29) 2 
(14.29)** 
13 0 (0.00) 1 (7.69) 1 (7.69) 
    Trisomy21 1 
 
1 1 
    
    22qDS 0 
  
0 
    
Coarctation of the Aorta (CoA) 66 6 (9.09) 2 (3.03) 8 
(12.12)** 
61 1 (1.64) 1 (1.64) 2 (3.28) 
    Turner 5 5 1 5 
    
    Trisomy21 0 
  
0 
    
    22qDS 0 
  
0 
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Totals Including Causal 
Chromosomal Abnormalities 
 
Totals Excluding Causal 
Chromosomal Abnormalities 
 
Phenotype/Subphenotype Subjects Subjects 
with 
CNV 
Loss 
Subjects 
with 
CNV 
Gain 
Subjects 
with 
CNV 
Loss or 
Gain 
Subjects Subjects 
with 
CNV 
Loss 
Subjects 
with 
CNV 
Gain 
Subjects 
with 
CNV 
Loss or 
Gain 
Double Inlet Left Ventricle (DILV) 19 0 (0.00) 1 (5.26) 1 (5.26) 19 0 (0.00) 1 (5.26) 1 (5.26) 
    Trisomy21 0 
  
0 
    
    22qDS 0 
  
0 
    
Double Outlet Right Ventricle 
(DORV) 
42 1 (2.38) 3 (7.14) 4 
(9.52)** 
41 0 (0.00) 2 (4.88) 2 (4.88) 
    Trisomy21 0 
  
0 
    
    22qDS 1 1 1 1 
    
Ebstein's Anomaly (EBSTEINS) 9 0 (0.00) 1 (11.11) 1 (11.11) 9 0 (0.00) 1 (11.11) 1 (11.11) 
    Trisomy21 0 
  
0 
    
    22qDS 0 
  
0 
    
Hypoplastic Left Heart Syndrome 
(HLHS) 
140 2 (1.43) 5 (3.57) 7 
(5.00)** 
138 0 (0.00) 4 (2.90) 4 (2.90) 
    Turner 2 2 
 
2 
    
    Trisomy21 0 
  
0 
    
    22qDS 0 
  
0 
    
Interrupted Aortic Arch (IAA) 11 4 (36.36) 0 (0.00) 4 
(36.36)** 
7 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 0 
  
0 
    
    22qDS 4 4 
 
4 
    
Mitral Valve Stenosis (MS, 
subvalvar, parachute) 
6 1 (16.67) 0 (0.00) 1 (16.67) 5 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 0 
  
0 
    
    22qDS 1 1 
 
1 
    
Other, Cardiac 18 1 (5.56) 2 (11.11) 3 
(16.67)** 
16 0 (0.00) 1 (6.25) 1 (6.25) 
    Trisomy21 1 
 
1 1 
    
    22qDS 1 1 
 
1 
    
Pulmonary Atresia (PA) 
    
16 0 (0.00) 0 (0.00) 0 (0.00) 
-IVS- 18 0 (0.00) 2 (11.11) 2 
(11.11)** 
    
    Trisomy21 1 
 
1 1 
    
    XXX 1 
 
1 1 
    
    22qDS 0 
  
0 
    
-VSD- 34 10 
(29.41) 
1 (2.94) 11 
(32.35)** 
24 0 (0.00) 1 (4.17) 1 (4.17) 
    Trisomy21 0 
  
0 
    
    22qDS 10 10 
 
10 
    
Subaortic stenosis 12 0 (0.00) 3 (25.00) 3 
(25.00)** 
11 0 (0.00) 2 (18.18) 2 
(18.18)** 
    Trisomy21 1 
 
1 1 
    
    22qDS 0 
  
0 
    
Supravalvar AS 4 3 (75.00) 0 (0.00) 3 
(75.00)** 
1 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 0 
  
0 
    
    Williams 3 3 
 
3 
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Totals Including Causal 
Chromosomal Abnormalities 
 
Totals Excluding Causal 
Chromosomal Abnormalities 
 
Phenotype/Subphenotype Subjects Subjects 
with 
CNV 
Loss 
Subjects 
with 
CNV 
Gain 
Subjects 
with 
CNV 
Loss or 
Gain 
Subjects Subjects 
with 
CNV 
Loss 
Subjects 
with 
CNV 
Gain 
Subjects 
with 
CNV 
Loss or 
Gain 
    22qDS 0 
  
0 
    
Tetralogy of Fallot (TOF) 73 11 
(15.07) 
10 
(13.70) 
21 
(28.77)** 
57 2 (3.51) 3 (5.26) 5 
(8.77)** 
    Trisomy18 1 
 
1 1 
    
    Trisomy21 6 
 
6 6 
    
    22qDS 9 9 
 
9 
    
Tricuspid Atresia (TRI-AT) 29 0 (0.00) 2 (6.90) 2 (6.90) 29 0 (0.00) 2 (6.90) 2 (6.90) 
    Trisomy21 0 
  
0 
    
    22qDS 0 
  
0 
    
Truncus Arteriosus (TA) 29 14 
(48.28) 
1 (3.45) 14 
(48.28)** 
17 2 (11.76) 1 (5.88) 2 
(11.76)** 
    Trisomy21 0 
  
0 
    
    22qDS 12 12 
 
12 
    
Vascular ring and PA sling 14 1 (7.14) 1 (7.14) 2 
(14.29)** 
12 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 1 
 
1 1 
    
    22qDS 1 1 
 
1 
    
VSD inlet 4 0 (0.00) 2 (50.00) 2 
(50.00)** 
2 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 2 
 
2 2 
    
    22qDS 0 
  
0 
    
Ventricular Septal Defect (VSD 
perimembranous) 
73 5 (6.85) 15 
(20.55) 
19 
(26.03)** 
57 2 (3.51) 2 3 (5.26) 
    Trisomy21 13 
 
13 13 
    
    22qDS 3 3 
 
3 
    
Ventricular Septal Defect (VSD 
subarterial) 
7 0 (0.00) 1 (14.29) 1 (14.29) 6 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 1 
 
1 1 
    
    22qDS 0 
  
0 
    
**Significance over both CHOP and MFHS controls (P ≤ 0.05). Four patients had both 
gains and losses but are only counted once in the column “Subjects with CNV Loss or 
Gain”. The following subphenotypes contained 0 subjects with a CNV and were 
therefore removed from the table: Arrhythmias (Congenital Heart Block, Long QT, 
WPW), 7; Cardiomyopathy (DILATED), 13; Cardiomyopathy (HYPERTROPHIC), 4; 
Chest Wall, 4; Coronary Arteries (COR ART), 10; L-TGA, 7; Dilated Ascending Aorta 
(MARFAN), 8; Partial Anomalous Pulmonary Venous Return (PAPVR), 12; Pulmonary 
Stenosis (Valvar), 9; Shone's, 8; Total Anamolous Pulmonary Venous Connection 
(TAPVC; infracardiac, intracardiac, mixed, supracardiac), 15; Transposition of Great 
Arteries (IVS), 21; (VSD), 20; and Ventricular Septal Defect (VSD multiple + 
muscular), 10 (n = 161 total). 
CNV gene frequency analysis and gene enrichment.  
In addition, CNV frequency “spectra” were computed as a 
proportion of each cohort containing a gain or a loss over 100 CHD 
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genes of interest (Fig. 4). (Spectra for individual CHD subphenotypes 
with statistically higher CNV frequencies are represented in Fig. 5.) 
The frequency of genes with gain or loss was compared with both 
control cohorts and significantly enriched genes are listed in Table 7. 
In addition, Supplemental Table S1 includes a complete summary of all 
CNV profiles over the 100 CHD risk gene list for each CHD subject, and 
a heatmap (Supplemental Fig. S1) illustrates the clustering of various 
groups of multiple subjects who share contiguous blocks of deleted or 
duplicated genes. 
 
Fig. 4. CNV frequency spectrum. Note that any gene showing 0% CNV frequency in all 
3 cohorts was omitted from this figure due to space considerations. Vertical error bars 
drawn represent 1 SD from the mean in the estimated sampling distribution. From this 
visualization it is clear that gains over gene FKBP6 on chromosome 7 occur in all 3 
cohorts, while losses of the same gene are only seen in the CHD cohort, implying a 
loss could cause CHD. 
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Fig. 5. CNV frequency spectra of significantly enriched phenotypes. Note that any 
gene showing 0% CNV frequency in all 3 cohorts was omitted from this figure due to 
space considerations. Vertical error bars drawn represent 1 SD in the estimated 
sampling distribution. Significantly enriched phenotypes included: aortic stenosis 
(valvar), atrioventricular canal (partial), atrioventricular septal defect (AVSD) with 
tetralogy of Fallot (TOF), subaortic stenosis, TOF, and truncus arteriosus. 
 
Table 7. CHD-associated gene regions significantly enriched with large, rare 
CNVs 
 Gains, % 
 
Losses, % 
 
Enriched For 
 
Gene CHD CHOP MFHS CHD CHOP MFHS Gains Losses 
PRKAB2 0.4 0.1 0.0 0.2 0.1 0.2 √  
FMO5 0.4 0.1 0.0 0.2 0.1 0.2 √  
CHD1L 0.4 0.1 0.0 0.2 0.1 0.2 √  
BCL9 0.3 0.1 0.0 0.2 0.1 0.2 √  
ACP6 0.3 0.1 0.0 0.2 0.1 0.2 √  
GJA5 0.3 0.1 0.0 0.2 0.1 0.2 √  
FKBP6 0.3 0.1 0.3 0.3 0.0 0.0  √ 
ELN 0.0 0.0 0.0 0.3 0.0 0.0  √ 
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 Gains, % 
 
Losses, % 
 
Enriched For 
 
Gene CHD CHOP MFHS CHD CHOP MFHS Gains Losses 
GTF2IRD1 0.0 0.0 0.0 0.3 0.0 0.0  √ 
GATA4 0.1 0.0 0.0 0.3 0.0 0.0  √ 
HRAS 0.3 0.0 0.0 0.0 0.1 0.0 √  
GATA6 0.3 0.0 0.0 0.0 0.0 0.0 √  
RUNX1 8.5 0.0 0.0 0.0 0.0 0.0 √  
CRKL 0.4 0.0 0.3 4.2 0.1 0.0  √ 
TBX1 0.2 0.0 0.2 4.4 0.1 0.0  √ 
ATRX 0.2 0.0 0.0 1.9 0.0 0.0  √ 
GPC3 0.2 0.0 0.0 1.9 0.0 0.0  √ 
BCOR 0.2 0.0 0.0 1.9 0.0 0.3  √ 
ZIC3 0.2 0.1 0.0 1.9 0.0 0.0  √ 
FLNA 0.2 0.1 0.0 1.9 0.0 0.0  √ 
MID1 0.2 0.0 0.3 2.1 0.0 0.3  √ 
The statistical test applied was the Barnard's exact test. Of our 100 candidate genes, 
21 were found to be significantly enriched for CNVs (null hypothesis rejected P ≤ 0.05 
in both cohorts: CHD vs. CHOP and CHD vs. MFHS, see boldface). We used the full 
cohorts for genes in autosomal chromosomes, and only the female portion for any 
genes on chromosomes (Chr.) X or Y. This leaves 322/880 for MFHS, 416/945 for 
CHD, and an estimated 1,013/2,026 for CHOP, usable for testing on the Chr. X genes. 
Numerous genes were identified as significantly enriched (P ≤ 
0.05 against both control cohorts), including losses, FKBP6, ELN, 
GTF2IRD1, GATA4, CRKL, TBX1, ATRX, GPC3, BCOR, ZIC3, FLNA and 
MID1, and gains, PRKAB2, FMO5, CHD1L, BCL9, ACP6, GJA5, HRAS, 
GATA6, and RUNX1. These genes are identified in Table 7. 
The authors recognize that syndromic forms of congenital heart 
disease are relatively well understood; therefore, genes in 
chromosomal abnormalities known to be causally related to CHD were 
intentionally kept on the 100 candidate CHD risk gene list to contrast 
with CNVs found elsewhere. For instance, haploinsufficiency of the 
genes associated with William's Syndrome, FKBP6, ELN, and 
GTF2IRD1, identified the three William's Syndrome patients in the 
study.1 Losses of the TBX1 and CRKL genes are associated with 22qDS 
and were observed in deleted subjects.32,53 Turner syndrome subjects 
carrying losses on the chromosome X genes involving MID1, BCOR, 
ATRX, GPC3, ZIC3, and FLNA were identified, as well as a female 
subject (XXX) who was identified with gains over these chromosome X 
gene regions. In addition, duplications involving RUNX1 were primarily 
Trisomy 21 subjects. 
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Gains at 1q21.1 including PRKAB2, FMO5, CHD1L, BCL9, ACP6, 
and GJA5 were significantly enriched in this study; however, losses 
that were observed in both control cohorts as well as the CHD cohort 
were not. Interestingly, gains at 1q21.1 were previously reported in 
isolated sporadic TOF.18 In our case cohort we observed one subject 
(case 24) with TOF (2 contiguous CNVs, 0.6 and 1.6 Mb), one subject 
(case 20) with PA-VSD (1.5 Mb), and another (case 10) with CoA (1.5 
Mb). One complex subject (case 2) with AS valvar and Shone's had a 
shorter gain (418 kb) involving only PRKAB2, FMO5, and CHD1L in 
conjunction with a 1.8 Mb gain at 5q35.2, which included the NSD1 
gene. 
Chromosome 8p23.1 deletions involving GATA4 were enriched 
and have been reported as a cause of complex congenital heart 
defects and diaphragmatic hernia.51 These included subjects with AVC 
partial (case 6, 3.8 Mb loss), VSD perimembranous (case 34, 4.5 Mb 
loss), and ASD-SV (case 5, 304 kb loss). 
Three subjects had gains involving the HRAS gene. The first was 
found in a complex subject with coarctation of the aorta: in addition to 
a 284 kb duplication involving the HRAS gene the subject had Turner 
syndrome. The remaining two gains (case 12, 256 kb; case 22, 271 
kb) were found in subjects with DILV and subaortic stenosis, 
respectively (Table 5). Cardiovascular malformations are known to be 
related to Ras/MAPK pathway syndromes, and previous literature 
findings have reported associations of HRAS mutations in Costello 
Syndrome and with the subaortic stenosis phenotype.29 These gains 
involving HRAS appear to expand phenotypes related to the Ras/MAPK 
pathway. 
Enriched CNVs identified in Table 7 are previously reported or 
can be found in the Database of Chromosomal Imbalance and 
Phenotype in Humans Using Ensembl Resources (DECIPHER) with the 
exception of the gains involving GATA6. One of the three gains 
involving GATA6 was in a subject with Trisomy 18 with TOF. The 
remaining two subjects with CNV gains involving GATA6 were 1) a 
subject (case 31) with truncus arteriosus with a complex CNV over two 
CHD genes of interest, a 308 kb gain including GATA6, and a 1.2 Mb 
22q11.2 distal deletion involving MAPK1 (losses in the distal region of 
22q11.2 have previously been reported in subjects with truncus 
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arteriosus),2 and 2) a subject (case 35) with VSD perimembranous 
with two neighboring 6.1 and 6.9 Mb gains involving a gain on GATA6. 
Although sequence variants in GATA6 have been previously found to 
be associated with cardiac outflow tract defects,27 these gains have not 
been reported and suggest possible GATA6 triple sensitivity to 
conotruncal defects. 
Collapsing groups of phenotypes by recognized causal 
chromosomal abnormalities.  
To increase statistical power, a strategy for summing cohorts 
was employed; subphenotypes associated with T21, 22qDS, and 
Turner Syndrome (see Tables 4 and 6) were collapsed into three 
groups, respectively.33 We hypothesized collapsing subphenotypes into 
genetically related groups would increase power to detect additional 
related CNVs by phenotype. The three collapsed groups each 
demonstrated significant enrichment (P ≤ 0.05) of additional CNVs 
compared with both control cohorts (see Table 8 - Enriched Syndrome 
Genes and Fig. 6 - Spectra). Large, rare CNVs were significantly more 
frequent (P ≤ 0.05) in the groups of T21 subphenotypes and included 
gains involving GATA6 and RUNX1 and losses involving GATA4, SOX7, 
TBX1, and CRKL. Likewise, collapsing the HLHS, CoA, and AS (valvar) 
subphenotypes, which made up the Turner syndrome group, indicated 
significant gains involving the 1q21.1 gene regions, enriched losses 
involving the Chr. X genes, as well as gains involving GATA4, SOX7, 
EHMT1 (case 15), and HRAS and losses involving FOXC1 (case 3) and 
NOTCH1 (case 11). Although the T21 and 22qDS subclasses share 
some overlap of phenotypes (other cardiac, TOF, vascular ring/PA 
sling, and VSD perimembranous), it is interesting to note that the 
22qDS grouping also included gains involving the 1q21.1 genes as well 
as GATA6 and RUNX1. Significant CNV losses within the 22qDS 
subclasses involved TBX1 and CRKL. All CNVs identified through the 
collapsed phenotypes are listed in Table 8 and are reported in 
DECIPHER. 
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Table 8. Enriched syndrome genes 
  
22q Like 
 
T21 Like 
 
Turner Like 
 
CHOP 
 
MFHS 
 
Ch
r. 
Gene 
 
Gain, 
% 
 
Loss, 
% 
 
Gain, 
% 
 
Loss, 
% 
 
Gain, 
% 
 
Loss, 
% 
Gain, 
% 
Loss, 
% 
Gain, 
% 
Loss, 
% 
1 ACP6 √ 0.67 
 
0.33 
 
0.27 
 
0.27 √ 0.42 
 
0.42 0.05 0.05 0.00 0.23 
1 BCL9 √ 0.67 
 
0.33 
 
0.27 
 
0.27 √ 0.42 
 
0.42 0.05 0.05 0.00 0.23 
1 CHD1
L 
√ 0.67 
 
0.33 
 
0.27 
 
0.27 √ 0.84 
 
0.42 0.05 0.05 0.00 0.23 
1 FMO5 √ 0.67 
 
0.33 
 
0.27 
 
0.27 √ 0.84 
 
0.42 0.05 0.05 0.00 0.23 
1 GJA5 √ 0.67 
 
0.33 
 
0.27 
 
0.27 √ 0.42 
 
0.42 0.05 0.05 0.00 0.23 
1 PRKA
B2 
√ 0.67 
 
0.33 
 
0.27 
 
0.27 √ 0.84 
 
0.42 0.05 0.05 0.00 0.23 
6 FOXC
1 
 
0.00 
 
0.00 
 
0.00 
 
0.00 
 
0.00 √ 0.42 0.00 0.00 0.00 0.00 
8 GATA
4 
 
0.00 
 
0.33 
 
0.00 √ 0.55 √ 0.42 
 
0.00 0.00 0.00 0.00 0.00 
8 SOX7 
 
0.00 
 
0.33 
 
0.00 √ 0.55 √ 0.42 
 
0.00 0.00 0.00 0.00 0.00 
9 EHMT
1 
 
0.00 
 
0.00 
 
0.00 
 
0.00 √ 0.42 
 
0.00 0.00 0.00 0.00 0.00 
9 NOTC
H1 
 
0.00 
 
0.00 
 
0.00 
 
0.00 
 
0.00 √ 0.42 0.00 0.00 0.00 0.00 
11 HRAS 
 
0.00 
 
0.00 
 
0.27 
 
0.00 √ 0.42 
 
0.00 0.00 0.05 0.00 0.00 
18 GATA
6 
√ 1.00 
 
0.00 √ 0.55 
 
0.00 
 
0.00 
 
0.00 0.00 0.00 0.00 0.00 
21 RUNX
1 
√ 7.36 
 
0.00 √ 22.25 
 
0.00 
 
0.00 
 
0.00 0.00 0.00 0.00 0.00 
22 CRKL 
 
0.67 √ 13.38 
 
1.10 √ 3.57 
 
0.00 
 
0.00 0.00 0.05 0.34 0.00 
22 TBX1 
 
0.33 √ 14.05 
 
0.55 √ 3.85 
 
0.00 
 
0.00 0.00 0.10 0.23 0.00 
X ATRX 
 
0.00 
 
0.00 
 
0.27 
 
0.00 
 
0.00 √ 8.99 0.00 0.00 0.00 0.00 
X BCOR 
 
0.00 
 
0.00 
 
0.27 
 
0.00 
 
0.00 √ 8.99 0.00 0.00 0.00 0.31 
X FLNA 
 
0.00 
 
0.00 
 
0.27 
 
0.00 
 
0.00 √ 8.99 0.10 0.00 0.00 0.00 
X GPC3 
 
0.00 
 
0.00 
 
0.27 
 
0.00 
 
0.00 √ 8.99 0.00 0.00 0.00 0.00 
X MID1 
 
0.00 
 
0.00 
 
0.27 
 
0.00 
 
0.00 √ 10.11 0.00 0.00 0.31 0.31 
X ZIC3 
 
0.00 
 
0.00 
 
0.27 
 
0.00 
 
0.00 √ 8.99 0.10 0.00 0.00 0.00 
Boldface indicates significant values. 
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Fig. 6. CNV frequency spectra of collapsed phenotypes by syndrome. Note that any 
gene showing 0% CNV frequency in all 3 cohorts was omitted from this figure due to 
space considerations. Vertical error bars drawn represent 1 SD in the estimated 
sampling distribution. Turner phenotypes, T21 phenotypes, and 22qDS phenotypes. 
Additional findings of note include a gain involving TBX20 and 
loss involving SALL4. Three losses including TBX20 have been 
previously reported in subjects with CHD (ASD and VSDs).26,38 We 
identified a subject (case 26) with TOF with a 3.3 Mb gain involving 
TBX20 and an adjacent 4.7 Mb gain involving HOXA1, which has been 
reported in DECIPHER. Finally, we report a subject (case 32) with 
truncus arteriosus with a 1.8 Mb loss over the SALL4 gene, which has 
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not been previously reported. This segment included a loss over 
NFATC2, a regulator of cardiac transcription factors but was not 
included in our 100 gene list because likely causal variants have not 
previously been reported in humans in this gene.9 
Distribution of CNVs by subject.  
To characterize CHD study subjects with an approach more 
typically used in clinical genetics, CNVs were separated by size 
(whether or not they would be cytogenetically visible) and then the 
CHD WIKI site was employed to determine if remaining CNVs should 
be classified as involving a “syndromic” (two or more clinical features) 
or a “nonsyndromic” gene.1 Cytogenetically visible CNVs (category A) 
included chromosomal abnormalities ≥3 Mbps. This category contained 
subjects with Trisomy 21, 18; Turner; and XXX syndrome and 
represented ∼9% of the CHD cohort. Category B, contributing 6% to 
the overall CNV distribution, were those subjects with a CNV over a 
“syndromic-associated” CHD gene as reported by CHD WIKI.1 This 
subset contained 22qDS subjects (n = 42) with losses over the TBX1 
gene, William's Syndrome subjects, all with a phenotype of 
supravalvar aortic stenosis (n = 3) with losses over the ELN, 
GTF2IRD1, and FKBP6 genes. The “nonsyndromic” segment (category 
C) representing 1% of the CHD cohort was also defined by the CHD 
WIKI portal. Six CHD case subjects, contributing 1% to the total, had 
a CNV over one of the 100 CHD-associated genes; however, their 
category was considered unknown. Category E represented individuals 
with no CNV over our predefined 100 CHD risk gene list. An individual 
could only fit into one category where D>A>B or C (see Fig. 7). 
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Fig. 7. Distribution of CNVs in CHD cohort. Type A represents cytogenetically visible 
chromosomal abnormalities (≥3 Mbp), type B are those subjects with a CNV over a 
syndromic-associated CHD gene as reported by the CHD WIKI portal, type C are those 
recognized through CHD WIKI as nonsyndromic, type D are CNVs with an unknown 
category, and type E represents subjects with no CNV over our predefined 100 CHD-
associated genes. An individual can only fit into 1 category where D>A>B or C. 
Numbers are rounded to the nearest percentage. 
Complex CNVs.  
Four basic mechanisms are involved in the generation of a 
majority of CNVs: deletion, duplication, inversion, and related 
combinations.56 We were interested if CHD subjects were at increased 
risk for carrying multiple CNVs. In the current study, 125 CHD subjects 
were defined as complex (methods). We identified 100 of those with 
known CHD-associated syndromes (T21, 59; T18, 1; 22qDS, 31; 
Turner, 6; William's, 2; XXX Syndrome, 1). Of the remaining 25, 24 
contained likely causal CNVs for CHD as outlined in Table 5, whereas 
one subject contained a nonconfirmed CNV over a CHD-associated 
gene. Three complex subjects had CNVs on different chromosomes 
over two of our CHD associated genes of interest: subjects 2, 31, and 
33 (Table 5). In addition, two subjects from the CHD cohort were both 
syndromic with their additional CNV over a second gene of interest: a 
Turner syndrome subject had a gain involving the HRAS gene and a 
22qDS subject had an additional CNV involving a gain over the MAPK1 
gene. 
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It is interesting to note that applying the “complex” criteria to 
the MFHS control cohort also identified 10 subjects from the controls 
that met the complex analysis requirements. These subjects had gains 
over the genes FKBP6, MYH11, TERT, TBX1, CRKL, SH3PXD2B, and 
losses over the 1q21.1 gene region and MID1. 
Discussion 
CHD is a complex disease with demonstrated genetic etiology in 
a subset of patients. CNVs, viewed as an evolutionary driving force for 
new gene function resulting in improved survival and/or adaption to 
new environments and disease, contribute the largest component of 
natural human variation between any two individuals; indeed, CNVs 
contribute significantly more to inter-individual variation than 
SNPs.35,39,41 There is a broad range of CNV lengths. In this study we 
focused on large CNVs that can be detected with high accuracy and are 
relatively straightforward to confirm. It has previously been estimated 
that ∼65–80% of individuals have a large CNV (≥100 kb) and 
approximately three to seven CNV segments per individual.56 The 
average number of CNVs per subject in our CHD cohort supports these 
previous observations (Fig. 3). It is apparent that as CNV data 
continue to grow, the development of higher-resolution approaches 
will permit smaller CNV detection with better accuracy. This will 
potentially lead to additional disease association discoveries.23 
However, data suggest that common CNVs (CNPs) are likely to be 
lower penetrance risk factors, whereas rare CNV variants are more 
likely to carry highly penetrant disease risk factors.13 
Significant challenges remain in CNV disease-association studies 
at both the platform and analysis levels.37 The relationship between 
phenotype and gene dosage is complex. Our study represents a 
comprehensive data curation and filtering of CNVs involving 100 
recognized CHD risk genes detected in a large, anatomically 
phenotyped CHD population. We employed a strict algorithm to 
determine frequencies of CNVs involving regions that encompassed 
these CHD risk genes. The algorithm employed was very similar to a 
recent recommendation by Breckpot et al.6 for determining if CNVs 
detected in CHD patients are clinically relevant; herein we performed a 
comparison against two different control populations and an analysis 
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primarily based on known chromosomal abnormalities and gene 
content rather than more commonly used CNV detection approaches 
that prioritize by size. CNVs over these predefined gene regions were 
then used to search for relationships between cardiac phenotype and 
gene dosage. 
The novel analytical approach described herein identified known 
causal chromosomal abnormalities (including T21, T18, 22qDS, 
Turner, William's, and XXX Syndromes), which represent 14% of CHD 
subjects in this study, similar to previous observations.36 Overall, this 
descriptive study suggests that (after excluding well-established causal 
chromosomal abnormalities) large, rare CNVs in 100 well-defined CHD 
risk genes confers significant risk of CHD and is likely etiologic in 4.3% 
of CHD cases, similar to previous observations.6 Cardiac 
subphenotypes showing the most significant (P ≤ 0.05) enrichment of 
large CNV events were aortic stenosis (valvar), AV canal (partial), 
AVSD with TOF, subaortic stenosis, TOF, and truncus arteriosus. CNV 
frequency spectra analysis identified enriched genes (P ≤ 0.05): 
losses: FKBP6, ELN, GTF2IRD1, GATA4, CRKL, TBX1, ATRX, GPC3, 
BCOR, ZIC3, FLNA, and MID1; and gains: PRKAB2, FMO5, CHD1L, 
BCL9, ACP6, GJA5, HRAS, GATA6, and RUNX1. 1q21.1 gains were 
enriched in subjects with conotruncal defects and coarctation of the 
aorta. 8p23.1 losses were enriched in subjects with septal defects and 
gains involving HRAS were observed in subaortic stenosis and DILV. 
Cardiovascular malformations are known to be related to Ras/MAPK 
pathway syndromes and previous literature findings have reported 
associations of HRAS mutations resulting in increased hRAS signaling 
with the subaortic stenosis phenotype. Other common phenotypes 
occurring in patients with hRAS mutations (also known as Costello 
syndrome) are cardiac hypertrophy (usually typical hypertrophic 
cardiomyopathy) and arrhythmia (usually supraventricular tachycardia, 
especially chaotic atrial rhythm/multifocal atrial tachycardia or ectopic 
atrial tachycardia).43 Although DILV sometimes are associated with 
pulmonary stenosis we have not found any previous reports of hRAS 
mutations linked to this phenotype. Thus, our data appear to expand 
phenotypes related to the Ras/MAPK pathway. 
We hypothesized that CNV frequency spectra combined with 
detailed anatomic classes would define the impact of gene dosage in 
etiologic molecular pathways. One set of clues when searching for 
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genetic causes of CHD is given by the enrichment of CHD cases in 
various recognized causal chromosomal abnormalities such as T21, 
T18, 22qDS, Turner syndrome, and William's Syndrome.36 For 
instance, three of four (75%) subjects in our study with supravalvar 
aortic stenosis had deletions involving FKBP6, ELN, and GTF2IRD1 
genes; all of these subjects had William's syndrome. In Turner 
syndrome, the incidence of CHD can be as high as 50% and include 
phenotypes such as BAV, CoA, ASD-VSD partially anomalus pulmonary 
vena cava, and HLHS, but these data vary.4 The specific cause for CHD 
in patients with Turner syndrome is currently unknown; several genes 
have been implicated but for the most part do not quite match Turner 
syndrome phenotypes or have only been associated with the syndrome 
by animal models.4,5 In the present study, eight Turner syndrome 
subjects were easily identified from the total CHD cohort by CNV 
frequency spectra analysis. In these subjects, copy number losses 
were present on all six of the Chr. X genes (MID1, BCOR, ATRX, GPC3, 
ZIC3, and FLNA) that were selected as CHD-associated from our list of 
100 genes. Two out of eight Turner cases in the study had HLHS, five 
had coarctation of the aorta, and one had aortic stenosis (valvar). 
Turner syndrome-associated phenotype percentages for the CHD 
cohort were in good agreement with published reports.4 
To test for additional CNV gene enrichment with increased 
power, subphenotypes associated with T21, 22qDS, and Turner 
Syndrome were collapsed in these groups, respectively. The three 
collapsed groups of subphenotypes each demonstrated enrichment (P 
≤ 0.05) in additional CNVs compared with both control cohorts. Large, 
rare CNVs significantly increased (P ≤ 0.05) in the groups of T21 
subphenotypes included gains over GATA6 and RUNX1 and losses over 
GATA4, SOX7, TBX1 and CRKL. Likewise, collapsing the HLHS, CoA, 
and AS (valvar) subphenotypes that made up the Turner syndrome 
group indicated significant gains over the 1q21.1 gene regions, 
enriched losses over the Chromosome X genes, as well as gains over 
likely etiologic genes such as GATA4, SOX7, EHMT1, and HRAS and 
losses over FOXC1 and NOTCH1. Although the T21 and 22qDS 
collapsed groups share some overlap of phenotypes, it is interesting to 
note that the 22qDS grouping also included gains over the 1q21.1 
genes, as well as GATA6 and RUNX1. Significant CNV losses within the 
22qDS subclasses were over TBX1 and CRKL. Incorporating gene 
dosage with detailed phenotyping into current molecular cardiogenesis 
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models may allow future models of development to fine tune and 
increase our understanding of etiologic pathways. 
By narrowing our focus on a select set of 100 well-known CHD 
risk genes, we limited the study by design. We focused on large rare 
CNVs in the current study; therefore, smaller CNVs have not yet been 
examined. Furthermore, the number of subjects per phenotype was 
small because of detailed anatomic groupings; collapsing into fewer 
groups (with larger n) according to developmental models would 
increase power and may permit identification of additional enriched 
genes. An additional foreseeable limitation was that CNVs may have 
been enriched in genes, but because the analysis required statistical 
significance with two control cohorts (where CNVs were not confirmed 
and may have been inflated and manifested as false positives), the 
study may not have been sufficiently powered to detect smaller but 
true differences. 
To our knowledge, this is the first paper to curate a large and 
diverse CHD population with regard to subphenotype and CNV 
frequency by gene region. This appears to be a useful approach to 
visualize and eventually, given sufficient numbers, to quantify relative 
risk of CNVs for specific subphenotypes. Broadening to encompass the 
entire genome and performing the copy number spectra analysis at 
higher resolution should identify additional candidate genes in CHD. 
The ability to quantify risk of particular cardiac malformations by gene 
dosage should offer insight into critical molecular pathways impacted 
during human cardiogenesis. Furthermore, overlaying CNV data and 
details of resulting cardiac phenotype with known functional pathways 
of cardiogenesis should lead to increased understanding of the 
molecular etiology of heart malformations. 
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